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Recent work shows potentially promising associations between schizophrenia and 
polymorphisms in Neuregulin-1 (NRG1). A large literature has also found strong familial 
relationships between schizophrenia and cognitive deficits. Given the role of NRG1 in 
glutamate-NMDAR regulation, we hypothesize that cognitive deficits may be related to sequence 
variation within NRG1, thus providing a possible mechanism by which NRG1 could act as a 
susceptibility gene for schizophrenia.  
This study examined the associations between NRG1, cognition, and schizophrenia using 
a multigenerational multiplex family sample (419 individuals from 40 families), including 58 
affected participants (schizophrenia or schizoaffective disorder, depressed type) and their 361 
unaffected relatives. In total, three samples were created from this participant pool: 1) the total 
sample, including affected and unaffected participants; 2) an unaffected subsample, consisting of 
only unaffected participants; and 3) the “No Diagnosis” subsample, consisting of participants 
with no diagnosis on the DIGS. In addition, a control group (N=199) was included for 
standardization of the cognitive data, but was not genotyped. Pedigree participants were 
genotyped using the SNPlex procedure for 40 NRG1 single nucleotide polymorphisms (SNPs). 
All participants completed structured diagnostic interviews and were administered a previously 
validated computerized neurocognitive battery that assessed eight cognitive   
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domains, including: abstraction/mental flexibility, attention, verbal/facial/spatial memory, 
spatial/emotional processing, and sensorimotor dexterity.  
Pedigree-based variance component quantitative trait analyses using SOLAR were 
performed to test for associations between individual NRG1 SNPs and cognitive performance.  
Although the specific associations that were significant differed somewhat among subsamples, 
each sample had between 14-25 significant (p≤0.05) associations, encompassing multiple SNPs 
and multiple cognitive domains. The numerous significant findings in progressively 
diagnostically “cleaner” sub-samples may suggest that variation in NRG1 is more directly 
associated with cognition and is not solely secondary to an effect of schizophrenia or 
psychopathology. These associations may suggest a role for NRG1 in cognition that is a 
mediating risk factor for schizophrenia and/or psychopathology more generally. It is also 
possible that these associations with cognition are irrelevant to schizophrenia, but the literature 
on NRG1 and schizophrenia argues against this possibility. 
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1.0  INTRODUCTION 
Schizophrenia is a disorder that is often characterized by hallucinations, delusions, and thought 
disorder in its acute phase. In the chronic phase of the illness, patients frequently suffer from 
negative symptoms, including blunted affect, loss of motivation, and poverty of speech. Despite 
these core similarities, patients vary considerably in their symptom profiles.  
 
1.1  REVIEW OF GENETIC FINDINGS IN SCHIZOPHRENIA 
Despite a great deal of research on the disorder, the details of its etiology remain largely 
unknown. Family, twin, and adoption studies have consistently suggested that genetic variation 
is the most important overall factor, with estimates of heritability (h2) in the range of 0.80-0.85 
(Cardno & Gottesman, 2000; Sullivan, Kendler, & Neale, 2003). Despite this knowledge, the 
genetic architecture of schizophrenia presents many complications, including a complex, 
polygenic transmission (Gottesman & Shields, 1967), reduced penetrance (Risch, 1990), and 
possible gene-environment and epistatic interactions. This complexity has made progress 
difficult and has slowed the elucidation of the molecular genetics of schizophrenia.  
One method of identifying candidate genes for genetic disorders is linkage studies. 
Although the regions identified through linkage may be quite large and power may be quite low 
without very large sample sizes, more than twenty genome-wide linkage studies of schizophrenia 
have been published to date. Combined, they implicate a large percentage of the human genome 
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in the pathogenesis of the disorder, although many of the findings have failed upon replication. 
Two recent meta-analyses have reassessed these inconsistencies through the utilization of more 
stringent statistical methods, resulting in a significant reduction in the number of potential 
positional candidate regions. Only two loci were identified by both studies: 8p and 22q (Badner 
& Gershon, 2002; C. M. Lewis et al., 2003).  
These difficulties with weak linkages have led researchers to test specific variants within 
or near a gene of interest using genetic association methods. Association studies correlate the 
frequency of certain alleles or haplotype combinations with phenotypic individual differences. 
Findings of association, however, are not necessarily causal. Instead, it may be that the observed 
variant and the unknown causal allele are in linkage disequilibrium (LD) with each other 
(Scolnick, Petryshen, & Sklar, 2006).  
As with linkage analyses, many polymorphisms have been reported to be associated with 
schizophrenia and yet have failed to replicate upon further study. Only a handful of genes have 
been commonly replicated, however, including: neuregulin-1 (NRG1), catechol-O-methyl 
transferase (COMT), dysbindin (DTNBP1), regulator of G-protein signaling 4 (RGS4), 
metabotropic glutamate receptor 3 (GRM3), disrupted-in-schizophrenia 1 (DISC1), and others 
(see Harrison & Weinberger, 2005 for a review). In all, linkage and association studies have 
identified over 130 potential susceptibility genes, each with small effect sizes and inconsistent 
replication attempts (Carter, 2006).  
Some of the variation in results across studies may be due to variation in allele frequency 
across samples. The power to detect associations between genes and disease phenotypes depends 
on allele frequencies, so some differences among studies may reflect allele frequency variation 
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between populations. In fact, important associations may be missed if the frequency of the allele 
in question is low in the population (Gardner et al., 2006). 
Another puzzling aspect of these studies is that several have found that the same loci 
confers risk to schizophrenia, but some find that the risk allele is an Adenine, for example, while 
the others find that the risk allele is a Guanine. There are several possible explanations for this 
phenomenon, including differences in population substructure or differences in the haplotype 
background (Duan et al., 2005). However, it has also been theorized that these findings are proof 
of the null hypothesis, suggesting that disparate findings prove that there is no association 
between the gene and trait of interest. 
 
1.2  NEUREGULIN-1 & SCHIZOPHRENIA 
Based on a history of positive linkage to chromosome 8 and significant association findings, 
NRG1 is one of the strongest positional and functional candidates for schizophrenia, among a 
large number of putative susceptibility genes that have been suggested (Harrison & Law, 2006).  
The neuregulin family of genes is a complex one, however. There are four members 
within the gene family, all of which are structurally-related glycoproteins that function as ligands 
for receptor tyrosine kinases of the ErbB family (Scolnick et al., 2006; Wolpowitz et al., 2000). 
NRG1 is a large gene, encompassing 1.3 million bases and including at least 21 exons 
(Steinthorsdottir et al., 2004). Approximately 0.3% of the gene codes for protein (Scolnick et al., 
2006), and there are at least nine alternative promoters and 16 alternative splicing isoforms 
(Steinthorsdottir et al., 2004).  
NRG1 was initially identified as a candidate gene for schizophrenia by a linkage study of 
Icelandic multiplex families with the disorder (Stefansson et al., 2003). Previous studies had 
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identified the 8p region, specifically 8p22-p11, as possessing one or more genes related to 
schizophrenia (Pulver et al., 1995). Careful mapping of this locus by Stefansson, et al. (2002) 
identified NRG1 as a specific candidate gene in that region. Using haplotype association and 
transmission disequilibrium tests (TDT), the group identified a risk haplotype in the 5’ end of the 
gene. This combination of variants is referred to as the HapICE haplotype.  
This initial study was subsequently replicated by the same research group in a Scottish 
population (Stefansson et al., 2003) and to date, nearly 50 replications have been conducted, with 
most of them finding evidence of an association between schizophrenia and NRG1 
(SchizophreniaGene, 2009). Specifically, with case-control (C-C) association designs, 17/30 
studies found a positive association between NRG1 and schizophrenia, while 10/19 family-based 
association tests (FBAT) found positive results. Overall, the estimates of relative risk (RR) lie 
between 1.0 and 2.2 for specific variants and haplotypes (Tosato, Dazzan, & Collier, 2005).  
In addition, these associations have not been limited to schizophrenia in any one 
population (SchizophreniaGene, 2009). In studies using Caucasian samples only, 10/17 C-C and 
4/10 FBAT studies found positive associations between NRG1 variants and schizophrenia. In 
Asian samples, 6/10 C-C and 4/5 FBAT studies found positive results. In less frequently studied 
populations, the results varied somewhat (African American samples: 1/1 C-C studies found 
positive results; Hispanic samples: 0/1 FBAT studies found positive results; mixed ethnicity 
samples: 0/2 positive C-C findings and 2/3 positive FBAT studies).  
An alternate explanation of these findings, as for all association studies, is that the 
variants and haplotypes suggested to be associated with schizophrenia are actually in LD with 
other causative variants in chromosome 8 (Scolnick et al., 2006). Although this remains a 
concern for all association studies, there have been no other genes identified within 500kb of 
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either the 5’ or 3’ ends of NRG1 (Li, Collier, & He, 2006). This relative isolation makes it less 
likely that the association of this region with schizophrenia is due to LD with another causal 
gene. In the case of NRG1, Gardner et al. (2006) found that there are extreme differences across 
different populations in the frequencies of specific variant alleles and haplotypes. They suggest 
that these findings show clear evidence of haplotype clustering according to population and 
continental region, and that local selective forces may be influencing the gene. Nevertheless, 
although the specific loci that are significant between patients and controls vary somewhat 
between studies, most have found that some variants within NRG1 do associate with 
schizophrenia, regardless of population (SchizophreniaGene, 2009). 
 
1.3 HYPOTHESIZED ROLE OF NRG1 IN SCHIZOPHRENIA 
NRG1 plays an integral role in the development, organization, and function of the central 
nervous system (CNS). In general, it is described as a pleiotropic growth factor (Li et al., 2006). 
At least twelve functions have been identified for this gene, including hormonal control of 
puberty, modulation of long-term potentiation (LTP), regulation of N-methyl-D-aspartic acid 
(NMDA), GABAA, and nicotinic receptors, and control of neuronal migration and differentiation 
(Harrison & Law, 2006). Because of this gene’s role in the organization and development of 
basic CNS structures, as well as its role in the regulation of NMDA glutamate receptors 
throughout the lifespan, this gene may also be of functional importance in schizophrenia 
(Harrison & Law, 2006). 
The potential relevance of these functions to schizophrenia is clear. There are several 
common neurobiological findings in this area: patients have decreased brain volume and 
enlarged ventricles (R. E. Gur et al., 2000; Honea, Crow, Passingham, & Mackay, 2005), 
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widespread abnormalities in cerebral blood flow (Brewer et al., 2007; Emri et al., 2006), and 
significant differences in neuronal density and migration ((Sei et al., 2007); Weinberger & 
Marenco, 2003) when compared to control groups. Variation in NRG1 may lead to incorrect 
CNS organization during development, in addition to any effects it has on synaptic “remodeling” 
in response to stressful experiences of the individual (Stefansson, Steinthorsdottir, Thorgeirsson, 
Gulcher, & Stefansson, 2004) or due to learning. 
In addition, although the focus of much of the research on the biological basis of 
schizophrenia has been on dopamine receptors, the role of other neurotransmitters, specifically 
glutamate, cannot be ignored. The postulated biological relevance of NRG1 in schizophrenia is 
based on the glutamate hypothesis which arose from the phencyclidine (PCP) model of 
schizophrenia. Luby et al. (1959) found that when normal controls were given a subanesthetic 
dose of PCP, they displayed many of the symptoms that patients with schizophrenia suffered 
from, including psychosis, thought disorder, cognitive impairment, and apathy. The chemical 
cascade of PCP was later discovered and suggested that psychosis induced by this substance was 
the result of a non-competitive blockage of NMDA glutamate receptors (Javitt & Zukin, 1991; 
D. M. Thompson & Moerschbaecher, 1984; D. M. Thompson, Winsauer, & Mastropaolo, 1987).  
Additional studies of NMDA antagonists, such as ketamine and MK-801, confirmed the 
role of glutamate in the manifestation of psychotic symptoms in normal controls, as well as the 
exacerbation of these symptoms in patients with schizophrenia (Carlsson, Waters, & Carlsson, 
1999; Stefansson et al., 2003). In humans, studies of postmortem tissue have shown significant 
changes to glutamate receptor protein expression, binding, and transcription between patients 
with schizophrenia and controls (Konradi & Heckers, 2003; D. A. Lewis & Moghaddam, 2006). 
These findings resulted in the NMDA-glutamate hypothesis of schizophrenia, and suggested that 
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a hypoglutamatergic state was present in at least some regions of the brain. This does not imply 
that other neurotransmitter systems, such as dopamine, do not have a role in the disorder; it 
simply makes the further evaluation of glutamate in schizophrenia very important.  
The putative role of NRG1 in this process lies in the influence NRG1 has on the expression 
of NMDA receptors through the activation of ErbB receptors. NRG1’s product is brought to the 
synapse through vesicle support where it diffuses across the synaptic cleft to bind to ErbB 
receptors (Stefansson et al., 2004). Activation of ErbB receptors by this protein results in the 
addition of an extra phosphate group to the ErbB receptors that are co-localized with NMDA 
receptors at post-synaptic density protein 95 (PSD95; Fischbach, 2006). This signal is then 
transduced by other kinases that regulate NMDA kinetic properties, leading to a reduction in the 
phosphorylation of the NMDA receptors upon the binding of NMDA or glutamate (Gu, Jiang, 
Fu, Ip, & Yan, 2005; Hahn et al., 2006).  
A recent study by Hahn et al. (2006) found that the levels of phosphorylation of activated 
NMDA receptors were reduced in brains from patients compared to controls. The authors 
suggest that enhanced endogenous NRG1-ErbB4 signaling may lead to a hypofunction of 
NMDA receptors, and thus a hypoglutamatergic state, such as that which is hypothesized in 
schizophrenia. Accordingly, a change in NRG1 may lead to an increased level of 
phosphorylation of ErbB4, which would result in an even stronger interaction between ErbB4 
and PSD95. This interaction could lead to hypofunctionality of the NMDA receptors during 
acute periods, ultimately leading to a hypoglutamatergic state (Fischbach, 2006). Thus, 
variations within NRG1 may contribute to hypoglutamatergic states, potentially resulting in 
psychotic symptomology and schizophrenia.   
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1.4 COGNITION & SCHIZOPHRENIA 
Despite the varied presentation and course of patients’ symptoms, one symptom that is extremely 
common in schizophrenia is cognitive dysfunction. These deficits are relatively independent of 
illness state, and are usually global (Heydebrand, 2006). The association between cognitive 
deficits and schizophrenia is very strong. Even more striking is that similar deficits have also 
been identified in both persons who are at high-risk for developing the disorder, as well as the 
unaffected biological relatives of patients (Simon et al., 2007; Snitz, MacDonald, & Carter, 
2006; J. L. Thompson, Watson, Steinhauer, Goldstein, & Pogue-Geile, 2005). The familiality of 
this dysfunction in even unaffected relatives suggests that cognitive impairment is actually a 
more sensitive measure of liability than symptoms alone (Snitz et al., 2006; J. L. Thompson et 
al., 2005). 
Just as schizophrenia likely involves multiple neurotransmitter systems, the control of 
cognition also involves many factors, including multiple neurotransmitters. Of particular interest 
in this study is the effect that glutamate has on cognition. Glutamate is the major excitatory 
neurotransmitter in the brain and is integral to the development of long-term potentiation (LTP) 
(Robbins & Murphy, 2006; Tamminga, 2006).  
LTP is one of the mechanisms that controls neuronal plasticity, and is important for 
learning and memory. Previous studies have shown that blockages of NMDA-glutamate 
receptors by NMDA antagonists inhibit the development of LTP, impairing several cognitive 
abilities. Specific deficits due to NMDAR blockage have been documented in rodents and 
include: spatial working memory in the Morris water-maze escape task (Morris, Anderson, 
Lynch, & Baudry, 1986), object recognition (Winters & Bussey, 2005), memory encoding during 
a flavor-place association task (Day, Langston, & Morris, 2003), as well as attentional deficits 
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and a failure to habituate (Nilsson, Waters, Waters, Carlsson, & Carlsson, 2001). Glutamatergic 
antagonist administration in humans has also been shown to have an effect on multiple cognitive 
domains, including impairments in verbal and nonverbal memory (Newcomer et al., 1999; 
Parwani et al., 2005), proverbs interpretation, working memory and set-shifting, and increased 
distractability (Krystal et al., 1999). These findings suggest that multiple domains of cognitive 
functioning are significantly impaired when the level of glutamate is low. 
The results from these studies strongly suggest that NMDA-glutamate receptor integrity 
is important to normal functioning in several cognitive domains. Given the relationship between 
NRG1 and glutamate, it can be hypothesized that variation within NRG1 could potentially lead 
to significant differences in cognitive functioning in patients and their relatives.  
 
1.5 CONVERGENT VALIDITY 
The results of NRG1 studies of schizophrenia generally suggest that NRG1 is a potential 
susceptibility gene for this disorder. There is a large literature supporting the positional relevance 
of the gene, as well as new information which makes it an intriguing functional candidate, 
suggesting that the relationship between NRG1 and schizophrenia should be more thoroughly 
evaluated. Furthermore, because NRG1 is thought to decrease glutamate levels in the brain, and 
because glutamate is important in cognitive abilities, a very common deficit in patients and their 
relatives, evaluating the relationship of NRG1 and cognition is essential to understanding 
NRG1’s potential role in schizophrenia. 
In order to identify true susceptibility genes and variants rather than false positives, 
methods that attempt to take into account the relationship between genes and correlates of 
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schizophrenia may be helpful. One strategy, convergent validity, may increase the understanding 
of the small and inconsistent findings of previous molecular studies in this way.  
Convergent validity is a technique which utilizes a secondary measure to elaborate the 
relationship between two variables (Campbell & Fiske, 1959). This type of validity is confirmed 
by the correlation between the primary and secondary measurements. Thus, if A is correlated 
with B, and B is correlated with C, a hypothesis of convergent validity would expect A to also be 
correlated with C. For example, in order to evaluate convergent validity for a candidate gene that 
may be associated with schizophrenia, the gene is correlated with another characteristic that is an 
important associate of the diagnosis. Given the aim of better understanding genetic effects in 
schizophrenia, this secondary phenotype should be a strong familial correlate of the disorder.  
In particular, we utilized this strategy to assess the relationship between one of the 
strongest candidate genes in schizophrenia, NRG1, and one of the strongest familial correlates of 
the disorder, cognitive deficits. Studies have consistently found that patients with schizophrenia 
have pervasive deficits in cognition, largely independent of symptom state, chronicity, and 
cognitive domain being tested (Heinrichs, Ruttan, Zakzanis, & Case, 1997; Snitz et al., 2006). 
Studies of unaffected relatives of patients also show significant cognitive impairments (Cannon 
et al., 1994; Grove et al., 1991; Snitz et al., 2006). As with patients, these deficits seem to be 
general across tasks, although such hypotheses are difficult to evaluate. Together, these findings 
strongly suggest that cognitive impairment is a strong familial correlate of schizophrenia.  
In addition to NRG1 and cognitive functioning both being important correlates of 
schizophrenia, the potential effects of NRG1 variation on glutamate function and glutamate’s 
role in cognition provide a potential mechanism by which cognitive deficits may also be related 
to variation within NRG1, and possibly offering a way by which NRG1 acts as a susceptibility 
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gene for schizophrenia. Pairing cognition with NRG1 can serve as a method of convergent 
validity when assessed within families affected by schizophrenia.  
 
1.6 REVIEW OF PREVIOUS STUDIES OF NRG1 & COGNITION 
To specifically test the role NRG1 may have on cognition through its role in glutamate and 
NDMAR regulation, researchers have developed transmembrane hypomorphic mutant mice. 
Such studies have found that these mice are hyperactive and have moderate prepulse inhibition 
deficits, both of which are reversible by the antipsychotic medication clozapine (Stefansson et 
al., 2002). Subsequent studies also found that these mice had habituation-exploration deficits 
(O'Tuathaigh, Babovic, O'Meara et al., 2007) and impaired regulation of reciprocal social 
interactions (O'Tuathaigh et al., 2008). However, negative studies of spatial learning and 
working memory with regard to NRG1 variation have also been published (O'Tuathaigh, 
Babovic, O'Sullivan et al., 2007).  
Six previous studies assessing specific NRG1 variants and cognition in humans have 
found mixed results. The most commonly assessed NRG1 variant in studies of cognition was 
SNP8NRG221533 (renamed: rs35753505). In normal controls, SNP8NRG221533/ rs35753505 
was found to have no effect on working memory tasks (Krug et al., 2008). The same SNP was 
tested in patients with schizophrenia, finding significant effects on the blood flow in several 
regions, including the hippocampus, cerebellum, and both the posterior and anterior cingulate 
cortices (Kircher et al., 2008). However, that SNP was not associated with task performance in 
the same sample (Kircher et al., 2008). This SNP was also found to be associated with sustained 
attention in a sample of Greek male military conscripts (Stefanis et al., 2007). 
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Another NRG1 variant commonly studied in the context of cognition was 
SNP8NRG243177 (renamed: rs6994992). One study found no association between SNP 
SNP8NRG243177/rs6994992 and premorbid IQ on a composite measure of general 
neurocognitive performance in patients (Crowley et al., 2008), while another found an 
association between the same marker and lower premorbid IQ and lower fronto-temporal 
activation in patients (Hall et al., 2006), as well as a significant effect on verbal IQ and brain 
activation in verbal fluency tasks in participants at high-risk for developing the disorder (Hall et 
al., 2006). A third study found that SNP8NRG243177/rs6994992 was moderately associated 
with spatial working memory in a sample of Greek male military conscripts (Stefanis et al., 
2007).  
Two other variants, rs10503929 and microsatellite 433E1006, have also been assessed in 
the context of cognition. Hong et al. (2008) analyzed the association between rs10503929 and 
prepulse inhibition (PPI) in individuals with schizophrenia and healthy controls, finding that the 
marker was not associated with either PPI or schizophrenia in that sample. Microsatellite 
433E1006 was tested for association with cognition in a study of Greek male military conscripts, 
finding that it was modestly associated with sustained attention and verbal working memory 
(Stefanis et al., 2007). 
 
1.7 AIMS & RATIONALE 
The specific questions that this study aimed to address were: 
1) Is cognition heritable in this multiplex family sample of schizophrenia? Trait heritability is 
a prerequisite for performing genetic association analyses.  
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2) Is variation in NRG1 associated with cognitive performance in patients and relatives of 
schizophrenic patients? If so, that would suggest that NRG1’s mechanism of increasing risk 
for schizophrenia may be due, in part, to its relationship to cognition. If, however, the 
variation within NRG1 is not associated with cognitive performance, this would suggest 
that NRG1’s putative mechanism of increasing risk for schizophrenia is unrelated to 
cognition.  
3) Assuming a significant relationship between cognition and NRG1 exists, do these 
associations remain in diagnostically cleaner sub-samples of the participant pool? If the 
relationship remains in samples without psychopathology, this may imply that cognition 
may mediate the association between NRG1 and schizophrenia. It may also be the case that 
NRG1-cognition associations are unrelated to schizophrenia, but findings of association 
between NRG1 and schizophrenia suggest against this idea. 
4) Is NRG1 associated with schizophrenia in this study? Despite the fact that our patient 
sample is small, we wanted to determine if there was a positive association between our 
gene of interest and the disorder in this study to assess generalizability.  
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2.0  METHODS 
2.1  PARTICIPANTS 
Written informed consent was obtained after the study procedures had been fully explained in 
accordance with the Institutional Review Boards of the University of Pittsburgh (PITT), 
University of Pennsylvania (PENN), and the Southwest Foundation for Biomedical Research. 
For participants younger than the age of 18, both the participant’s and parents’ consents were 
obtained.  
 
2.1.1  Recruitment & Inclusion Criteria 
Probands and their family members were identified through mental health and consumer 
organizations in Pennsylvania, New Jersey, Delaware, Ohio, West Virginia, Kentucky, 
Michigan, and Indiana. Probands were included if they had a diagnosis of schizophrenia, were of 
European-American origin, 18 years or older, and competent to provide informed consent. In 
addition, they also had to have one or more first degree relatives with a diagnosis of 
schizophrenia or schizoaffective disorder-depressed type, and have a large, multigenerational 
family with ten or more first and second degree relatives. Probands were excluded if they did not 
provide consent to contact their family members, their IQ was lower than 70, they were not 
proficient in English, and/or their diagnosis was complicated by substance use, effects of 
prescription medications, or medical conditions.  
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Relatives had to be 15 years or older and willing to provide signed consent. Exclusion 
criteria for this group included: IQ < 70; not being proficient in English; and/or a CNS disorder 
that would interfere with the interpretation of cognitive measures. If, however, relatives met 
diagnostic criteria for schizophrenia or schizoaffective disorder-depressed type, but did not meet 
inclusion criteria, blood samples, but no neurocognitive testing, was obtained.  
Control participants were recruited from the same areas as patients and relatives and were 
included if they met the inclusion/exclusion criteria during a standardized screening. Recruitment 
at the PITT site was done through random digit dialing in the area codes where probands and 
family members were recruited. After the study was described to potential participants, a 
telephone screen was used to exclude those with psychosis or cognitive disorders. In addition, 
potential control participants were matched as a group to index family members on age, sex, and 
ethnic background. All participants who passed the telephone screen and matching criteria were 
consented for the study and interviewed with the Diagnostic Interview for Genetic Studies, 
administered a computerized neurocognitive battery, and had blood drawn for DNA collection. 
Finally, consensus diagnosis was carried out for all PITT controls (see Procedures for more 
information).  
Recruitment for PENN controls was done through convenience sampling and word of 
mouth. A screening interview was used to detect psychotic or cognitive disorders and potential 
participants were group-matched with index family members on age, sex, and ethnic 
background. In addition, a second group of PENN controls was included whose data had been 
gathered prior to the current study. These controls were administered the same interview as the 
other PENN control participants to screen for psychotic or cognitive disorders. They also 
completed the neurocognitive battery and blood draw. For both sites, control participants were 
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excluded if they had any Axis I disorder with psychotic features or a cluster A personality 
disorder, if they were taking psychotropic medications, or had a first degree relative with 
psychosis. They also had to be medically and neurologically healthy.  
 
2.1.2  Description of the Sample 
In total, there were 1608 pedigree members (43 index probands and 1565 relatives) available for 
recruitment and 230 unrelated controls. As can be seen in Table 1, 675 pedigree members and 
230 normal controls of these individuals were enrolled in the overall study. A total of 603 
pedigree members and 218 controls completed the diagnostic portion of the study, and 568 
pedigree members and 199 controls also completed the cognitive battery (<10 missing test 
scores). Five hundred fifty-three of these pedigree members and 139 controls provided DNA. 
Thus, the final sample for the present study consisted of those remaining in the participant pool 
whose NRG1 genotypes were also successfully measured (see below for quality control 
measures), resulting in 419 pedigree members (23 index probands and 396 relatives) from 40 
multiplex, multigenerational families.  
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Table 1. Attrition of Participants 
 
As shown in Tables 2 and 3, family size within this final sample ranged from one to 38 
members (average members per family = 10.48, SD = 1.36), and the number of affected 
participants (with schizophrenia or schizoaffective disorder, depressed) per family in the final 
sample ranged from zero to four (average affected individuals per family = 1.45, SD = 5.61).   
 
  
      
 Pedigree Sample 
Controls Total Sample 
 Families Probands Relatives 
Total 
Pedigree 
Members 
Total Available Sample 43 43 1565 1608 230 1838 
Enrolled in Study 43 43 632 675 230 905 
Enrolled + Diagnosis 43 42 603 645 218 863 
Enrolled + Diagnosis + 
CNB 42 30 538 568 199 767 
Enrolled + Diagnosis + 
CNB + Blood drawn 42 30 523 553 139 692 
Enrolled + Diagnosis + 
CNB + Blood drawn + 
NRG1 
40 23 396 419 0 419 
Note. Computerized neurocognitive battery abbreviated CNB. Neuregulin-1 abbreviated NRG1. 
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Table 2. Frequency Distribution of Family Size in Final Sample 
Members in family* Count of Families 
1 3 
2 3 
3 0 
4 5 
5 3 
6 1 
7 4 
8 4 
9 1 
10 3 
11 1 
12 2 
13 0 
14 1 
15 0 
16 1 
17 0 
18 1 
19 0 
20 0 
21 1 
22 1 
23 0 
24 1 
25 1 
26 1 
27 0 
28 0 
29 0 
30 0 
31 1 
32 0 
33 0 
34 0 
35 0 
36 0 
37 0 
38 1 
Mean 10.48 
SD 1.36 
*Includes only those family members who 
completed all parts of the present study and 
are in the final sample 
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Table 3. Frequency of Affected Members per Family in the Final Sample 
Members with schizophrenia or 
schizoaffective disorder, 
depressed 
Count of Families 
0 7 
1 16 
2 11 
3 4 
4 2 
Mean 1.45 
SD 5.61 
*Includes only those members who completed all parts of 
the present study and are in the final sample 
 
As shown in Table 4, there were 86 first-degree relatives of the index proband, 88 
second-degree relatives, 97 third-degree relatives, 93 biological relatives extended past the third-
degree, and 32 non-biological relatives within the final sample. No controls were genotyped for 
NRG1, thus the final sample of controls included those who were enrolled and completed the 
diagnostic and cognitive portions of the study (N=199), without regard to whether DNA was 
collected. 
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Table 4. Demographics and Genetic Relationships in the Final Sample 
  
 N %Male 
Mean Age 
(SD) 
Age 
range 
Mean 
Education 
(SD) 
Education 
range 
%Right 
Handed %Pitt 
Probands 23 69.6% 42.3 (10.0) 22-54 12.5 (2.1) 9-17 91.3% 43.5% 
Relatives 396 49.2% 44.9 (16.9) 15-84 13.3 (2.9) 6-20 85.9% 43.4% 
  First-degree relatives 86 47.7% 47.7 (14.6) 16-84 12.6 (3.0) 7-20 84.9% 48.8% 
    Parent of proband 20 40.0% 62.8 (11.2) 43-84 11.8 (3.1) 7-18 80.0% 65.0% 
    Sibling of proband 56 50.0% 46.7 (9.3) 21-68 12.8 (3.0) 7-20 85.7% 41.1% 
    Child of proband 10 50.0% 23.7 (9.1) 16-47 12.6 (2.8) 9-17 90.0% 60.0% 
  Second-degree relatives 88 55.7% 46.9 (20.9) 15-82 12.9 (2.9) 6-20 80.7% 42.1% 
    
Grandparent of 
proband 3 66.7% 71.0 (1.0) 70-72 12.7 (3.5) 9-16 100.0% 100.0% 
    Aunt/Uncle of proband 42 57.1% 64.4 (10.9) 42-82 12.6 (2.8) 8-18 78.6% 40.5% 
    Half-sibling of proband 2 50.0% 31.5 (2.1) 30-33 11.0 (1.4) 10-12 100.0% 50.0% 
    
Niece/Nephew of 
proband 41 51.2% 27.9 (9.4) 15-56 13.2 (3.1) 6-20 80.5% 39.0% 
  Third-degree relatives 97 49.5% 44.7 (12.5) 17-74 13.9 (2.9) 9-20 88.6% 55.7% 
    1st cousin of proband 97 49.5% 44.7 (12.5) 17-74 13.9 (2.9) 9-20 88.6% 55.7% 
  Extended  relatives 93 45.7% 36.7 (16.6) 16-82 13.4 (2.7) 8-19 90.3% 40.9% 
  Non-biological relatives 32 43.8% 55.9 (11.6) 26-77 14.1 (2.9) 10-20 90.6% 3.1% 
Controls 199 42.7% 47.3 (19.1) 18-84 14.9 (2.8) 8-20 87.9% 44.2% 
  
The clinical composition of the final sample is shown in Table 5. One hundred percent of 
the probands were diagnosed with schizophrenia. In addition, 30.4% of the proband sample had a 
comorbid diagnosis of a substance-related disorder. Among relatives, 8.1% were diagnosed with 
schizophrenia and 0.75% were diagnosed as schizoaffective disorder-depressed type. In addition, 
9.1% were diagnosed with schizoaffective disorder, bipolar type, bipolar I or II, major 
depression with psychotic features, other organic or nonorganic psychosis, or cluster A 
personality disorder. In terms of non-psychotic affective disorders, 17.7% of relatives were 
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diagnosed with either major depression without psychotic features or another mood disorder 
(including mood disorders due to substance use or general medical conditions, and mood 
disorder NOS). Finally, 23.7% of relatives were diagnosed with a substance-related disorder. 
Among controls, 14.1% were diagnosed with major depressive disorder without psychotic 
features or another mood disorder, while 8.0% were diagnosed with a substance-related disorder. 
 
Table 5. Clinical composition of the Final Sample 
 
Proband  Relatives Controls 
N 23 396 199 
Schizophrenia 23 32 0 
Schizoaffective 
Disorder, 
Depressed 0 3 0 
Schizoaffective 
Disorder, 
Bipolar 0 2 0 
Bipolar I & II 0 5 0 
MDD with 
psychotic 
features 0 2 0 
Other 
Psychosis 0 9 0 
Cluster A 
Personality 
Disorder 0 18 0 
MDD without 
psychotic 
features 0 70 24 
Other Mood 
Disorder 0 43 4 
Substance-
related 
Disorder 7 94 16 
Cognitive 
Disorder 0 0 0 
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Pedigree members were further classified into two mutually exclusive groups, affected or 
unaffected, as shown in Tables 6 and 7. The affected group consisted of 58 individuals diagnosed 
with schizophrenia or schizoaffective disorder, depressed. The unaffected group consisted of 
individuals diagnosed with any disorder other than schizophrenia or schizoaffective disorder, 
depressed, and those with no diagnoses on the DIGS (N=361). This group included those with 
spectrum diagnoses (schizoaffective disorder, bipolar type, bipolar I or II, major depression with 
psychotic features, other psychoses, or a cluster A personality disorder; N=36), non-spectrum 
diagnoses (major depression without psychotic features, other mood disorder, or substance-
related disorder; N=147), and those with no diagnosis on the DIGS (N=178). In addition, 178 
participants had no diagnoses on the DIGS, creating a “No Diagnosis” group.  
 
Table 6. Demographic Information of the Final Pedigree Sample by Alternate Diagnostic 
Categories 
 
Affected^ Unaffected*^ 
No 
Diagnosis^ 
N 58 361 178 
%Male 67.20% 47.70% 40.50% 
Mean Age (SD) 43.7 (9.5) 44.9 (17.4) 45.9 (18.7) 
Age range 22-59 15-84 15-82 
Mean Education (SD) 12.5 (2.7) 13.4 (2.9) 13.5 (2.9) 
Education range 7-20 6-20 8-20 
%Pitt 41.40% 43.80% 46.10% 
Index Probands (%) 23 (100.00%) 0 (0.00%) 0 (0.00%) 
First-degree relatives (%) 28 (80.00%) 58 (16.10%) 27 (15.20%) 
Second-degree relatives (%) 2 (5.70%) 86 (23.80%) 49 (27.50%) 
Third-degree relatives (%) 2 (5.70%) 95 (26.30%) 48 (26.90%) 
Extended biological relatives (%) 3 (8.60%) 90 (24.90%) 37 (20.80%) 
Non-biological relatives (%) 0 (0.00%) 32 (8.90%) 17 (9.60%) 
*Affected and unaffected are mutually exclusive groups. Within the unaffected group, there  is a 
“no diagnosis” subgroup. 
^The affected group includes all participants with schizophrenia or schizoaffective disorder-
depressed. The unaffected group includes all participants with diagnoses other than 
schizophrenia or schizoaffective disorder-depressed, including those with no diagnoses on the 
DIGS.  
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Table 7. Clinical composition of the Final Pedigree Sample by Alternate Diagnostic Categories 
 
Affected*^ Unaffected*^ No Diagnosis 
N 58 361 178 
Schizophreniaº 55 0 0 
Schizoaffective Disorder, Depressedº 3 0 0 
Schizoaffective Disorder, Bipolarº 0 2 0 
Bipolar I & IIº 0 5 0 
MDD with psychotic featuresº 0 2 0 
Other Psychosisº 0 9 0 
Cluster A Personality Disorderº 0 18 0 
MDD without psychotic featuresº 0 70 0 
Other Mood Disorderº 6 37 0 
Substance-related Disorderº 19 82 0 
Cognitive Disorderº 0 0 0 
*Affected and unaffected are mutually exclusive groups. Within the unaffected group, there  is a “no 
diagnosis” subgroup. 
^The affected group includes all participants with schizophrenia or schizoaffective disorder-depressed. 
The unaffected group includes all participants with diagnoses other than schizophrenia or 
schizoaffective disorder-depressed, including those with no diagnoses on the DIGS. 
ºThe following categories are mutually exclusive:  schizophrenia, schizoaffective disorder-depressed, 
schizoaffective disorder-bipolar, Bipolar I & II, MDD with and without psychotic features 
 
 
2.1.3  Attrition Analyses 
Table 8 displays the demographics and genetic relationships of participants who were enrolled in 
the overall study, but did not complete one or more portions of the present study, and thus are not 
included in the final sample. The total pool of participants lost to attrition consisted of 287 
individuals (20 index probands, 236 relatives, and 31 normal controls). Diagnostic information 
on this sample can be found in Table 9.  
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Table 8. Demographics and Genetic Relationships in the Attritional Sample 
  
 N %Male 
Mean Age 
(SD) 
Age 
range 
Mean 
Education 
(SD) 
Education 
range %Pitt 
Probands 20 47.4% 51.5 (14.9) 20-82 12.0 (2.5) 8-16 36.8% 
Relatives 236 43.6% 47.3 (19.8) 15-97 13.0 (3.2) 4-20 35.6% 
  First-degree relatives 70 44.3% 54.1 (17.9) 24-89 13.3 (3.1) 8-20 40.0% 
    Parent of proband 23 30.4% 71.5 (11.5) 40-89 12.6 (3.4) 8-20 30.4% 
    Sibling of proband 42 50.0% 47.9 (13.9) 24-84 13.8 (3.1) 8-20 45.2% 
    Child of proband 5 60.0% 30.0 (5.8) 25-39 13.2 (1.6) 12-16 40.0% 
  Second-degree relatives 54 44.4% 47.2 (22.8) 15-97 12.5 (3.9) 4-20 35.2% 
    
Grandparent of 
proband 3 33.3% 82.0 (14.1) 69-97 7.0 (4.4) 4-12 33.3% 
    Aunt/Uncle of proband 17 41.2% 69.7 (13.3) 41-87 11.3 (3.5) 6-19 35.2% 
    
Half-sibling of 
proband 2 50.0% 26.5 (7.8) 21-32 10.5 (2.1) 9-12 50.0% 
    
Niece/Nephew of 
proband 32 43.8% 33.3 (12.5) 15-53 14.0 (3.3) 9-20 34.4% 
  Third-degree relatives 30 56.7% 44.4 (16.3) 15-77 13.4 (2.6) 8-18 46.7% 
    1st cousin of proband 30 56.7% 44.4 (16.3) 15-77 13.4 (2.6) 8-18 46.7% 
  Extended  relatives 58 36.2% 36.8 (16.7) 15-86 12.4 (2.7) 6-20 39.7% 
  Non-biological relatives 24 45.8% 56.9 (16.7) 28-87 14.3 (3.1) 9-20 0.0% 
Controls 31 45.2% 30.7 (9.4) 19-53 NA NA 0.0% 
*No education information was available for controls in the complement sample    
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Table 9. Clinical Composition of the Attritional Sample 
Proband Relatives Controls
N 20 207 31
Schizophrenia 19 25 0
Schizoaffective 
Disorder, 
Depressed
1 6 0
Schizoaffective 
Disorder, Bipolar
0 2 0
Bipolar I & II 0 3 0
MDD w ith 
psychotic 
features
0 2 0
Other Psychosis 0 8 0
Cluster A 
Personality 
Disorder
0 7 0
MDD w ithout 
psychotic 
features
0 47 0
Other Mood 
Disorder 2 16 0
Substance-
related Disorder
4 59 0
Cognitive 
Disorder 0 2 0
**29 relatives in the attritional sample have missing diagnostic information
* The follow ing categories are mutually exclusive:  schizophrenia, schizoaffective 
disorder-depressed, schizoaffective disorder-bipolar, Bipolar I & II, MDD w ithout 
psychotic features, and MDD w ith psychotic features. 
 
 
Comparisons were made between the final and attrition samples to determine the 
representativeness of the final sample. Probands in the final sample were significantly younger 
than probands lost to attrition (t=2.39, df=40, p=0.022), but no significant differences were found 
in sex, personal education, or parental education. No significant differences were detected for 
any demographic variables between the final and attritional relative samples. Finally, the controls 
in the final sample were significantly older than those in the attritional sample (t=-7.63, df=75.6, 
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p=0.000). Differences in personal and parental education could not be tested due to the absence 
of education information for the controls lost to attrition.  
Finally, comparisons between diagnoses present in the final and attritional sample were 
made to further determine the representativeness of the final sample. There were no significant 
differences between the frequency of specific diagnoses in the final and attritional sample of 
probands. Significantly fewer relatives had a diagnosis of schizoaffective disorder-depressed 
type, in the final sample when compared to the attritional sample (χ2=4.24, df=1, p<0.05). In 
addition, significantly more controls had a diagnosis of major depressive disorder, without 
psychotic features, in the final sample when compared to the attritional sample (χ2=4.17, df=1, 
p<0.05).  
 
2.2   PROCEDURES 
2.2.1  Diagnostic Assessment 
Clinical evaluation included the Diagnostic Interview for Genetic Studies, version 2.0 (DIGS) 
(Nurnberger et al., 1994), the Family Interview for Genetic Studies (FIGS) (Maxwell, 1992), and 
a review of medical records. Assessment was conducted by trained interviewers with established 
reliability under the supervision of investigators; however, interviewers were not blind to the 
status (proband, relative, control) of the individuals participating in the study. To further ensure 
reliability, investigators who had not evaluated the individual reviewed each case independently 
and provided DSM-IV multiaxial lifetime diagnoses, with differences being resolved by 
consensus. In addition, complex cases were discussed between sites. At each site, interrater 
reliability among investigators and interviewers was tested at regular intervals using videotaped 
interviews and bimonthly joint interviews. Each team of interviewers reviewed 10 videotaped 
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DIGS evaluations from the other site. Kappa values for exchanged tapes were maintained at or 
above 0.8. Finally, the two teams met twice a year for further diagnostic and reliability training. 
In place of the DIGS, 109 control participants from the PENN site were administered a 
diagnostic checklist to make diagnoses and rule-out schizophrenia-spectrum disorders.  
 
2.2.2  Neurocognitive Measures 
Participants were administered a computerized neurocognitive battery previously tested in both 
healthy and patient samples (R. C. Gur, Ragland, Moberg, Bilker et al., 2001; R. C. Gur, 
Ragland, Moberg, Turner et al., 2001). The battery took approximately 60 minutes to complete 
and was administered by research assistants using desktop or laptop computers. The tests 
included training modules and had automated scoring to ensure reliability of results. Tests were 
administered in a fixed order. Raw scores were converted to z-scores using the mean and 
standard deviation (SD) from the control group used in the present study. Z-scores for domains 
with more than one test (Emotional Processing) or with two conditions (Attention: letter and 
number) were calculated by converting the raw scores for both tasks to z-scores using the 
method described above and then averaging the standard scores. Domain scores for tasks with 
immediate and delayed conditions (Verbal, Facial, and Spatial Memory) were calculated by 
averaging the performance on both conditions and then converting the raw average to a z-score. 
Three performance indices were calculated: accuracy (number of correct responses), speed 
(median reaction time for correct responses), and efficiency (ratio of accuracy to the log of 
speed). The battery assessed the following domains (as previously reported in R.E. Gur et al., 
2007). 
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2.2.2.1 Abstraction and Mental Flexibility.  The Penn Conditional Exclusion Test (Kurtz, 
Ragland, Moberg, & Gur, 2004) presents four objects at a time, and the participant selects the 
object that does not belong with the other three based on one of three sorting principles. Sorting 
principles change and feedback guides their identification (time: 12 minutes).  
2.2.2.2 Attention. The Penn Continuous Performance Test (Kurtz, Ragland, Bilker, Gur, 
& Gur, 2001) uses a continuous performance test paradigm where the participant responds to 
seven-segment displays whenever they form a digit or letter, depending on the condition. 
Working memory demands are eliminated because the stimulus is present (time: 8 minutes).  
2.2.2.3 Verbal Memory. The Penn Word Memory Test (R. C. Gur et al., 1993) presents 
20 target words followed by an immediate recognition trial with targets interspersed with 20 
distractors equated for frequency, length, concreteness, and low imageability using Paivio’s 
norms. Delayed recognition is measured at 20 minutes (time: 4 minutes).  
2.2.2.4 Facial Memory. The Penn Face Memory Test (R. C. Gur et al., 1993) presents 20 
digitized faces subsequently intermixed with 20 foils equated for age, gender, and ethnicity. 
Participants indicate whether or not they recognize each face immediately and after a 20 minute 
delay (time: 4 minutes).  
2.2.2.5 Spatial Memory. The Visual Object Learning Test (Glahn, Gur, Ragland, Censits, 
& Gur, 1997) presents 20 Euclidean shapes subsequently interspersed with foils immediately and 
after a 20 minute delay (time: 4 minutes).  
2.2.2.6 Spatial Processing. Judgment of Line Orientation (A.L. Benton, N.R. Varney, & 
K.S. Hamsher, 1975.) is a computer adaptation of Benton’s test. Participants see two lines at an 
angle and indicate the corresponding lines on a simultaneously presented array (time: 6 minutes).  
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2.2.2.7 Sensorimotor Dexterity. The participant uses a mouse to click on squares 
appearing at varied locations on the screen (R. C. Gur, Ragland, Moberg, Turner et al., 2001). 
The stimuli become progressively smaller (time: 2 minutes).  
2.2.2.8 Emotion Processing. Identification of facial affect was tested with two 40-item 
tasks. During the Penn Emotion Recognition Task, participants labeled faces as being happy, 
sad, angry, fearful, or neutral. During the second task, the Emotion Intensity Discrimination Test 
(R. E. Gur et al., 2006), each stimulus was comprised of two faces of the same individual 
showing the same emotion (happy or sad) with different intensities. The participant selects the 
more intense expression. Sets were balanced for gender, age, and ethnicity (5 minutes).  
2.2.2.9 Outcome. To help ensure the validity of the cognitive data, participants with 
missing data on 10 or more tasks in the battery were excluded from analyses (N=27; 5 probands, 
3 relatives, and 19 controls). Missing data could have been the result of computer malfunction, 
participant’s unwillingness to complete the test, and/or data that was deemed invalid due to 
participant’s behavior during testing or non-standard testing conditions. In addition, controls 
recruited prior to the current study had higher rates of missing data due to tests added to the 
battery at a later time. Averaging over all of the tests in the computerized neurocognitive battery, 
the rate of missing data per test in the final sample was 4.7% (SD = 0.04), 2.1% (SD = 0.02), and 
4.2% (SD = 0.06) for probands, relatives, and controls, respectively. As shown in Table 10, 
average rates of missing data per person were 1.17, 0.52, and 1.11 domain scores for probands, 
relatives, and controls, respectively, out of 24 total domain scores.  
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Table 10. Frequency of missing CNB data in the Final Sample by Group 
Count of Missing 
Domain Scores Probands Relatives Controls 
  0 16 341 155 
  1 0 0 0 
  2 0 0 0 
  3 6 45 24 
  4 0 0 1 
  5 0 1 0 
  6 0 5 4 
  7 0 0 6 
  8 0 0 3 
  9 1 4 6 
  Mean 1.17 0.52 1.11 
   
 
2.2.3  Selection of SNPs & Primer Design 
Fifty-four SNPs were chosen for this study to fit one of several categories: primary, haplotype, 
other, and redundant primary. All SNPs had a minor allele frequency (MAF) of at least 5% in 
European American populations according to Ensembl (release 43), dbSNP (build 127), and 
HapMap (release 21a).  
“Primary” SNPs were those that were positively associated with schizophrenia by at least 
one study, resulting in 23 SNPs. Next, SNPs were chosen for coverage based on the haplotype 
blocks (e.g. HapICE, HapIRE, etc.). As many of the original haplotype markers were 
microsatellites, SNPs located near those microsatellites were chosen to attempt to capture that 
variation. All of the SNPs within these haplotype block areas were entered into HClust/R 
program to determine LD. This led to 19 non-redundant (r2 ≤ 0.80) “haplotype” SNPs. SNPs not 
listed in HapMap, and thus impossible to run through HClust, were included by default. The 
“other” category consists of SNPs from within exons or untranslated regions (UTR). Upon 
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proposal of the study, HapMap’s HapMart program (release 22) listed four nonsynonymous 
exonic SNPs (one of which was already a primary SNP) and one 5’ UTR, all of which were 
included in the SNP pool. By the conclusion of the study, newly published information on the 
structure of NRG1 resulted in HapMap’s HapMart program (release 23a) changing the 
categorization of two of the original four exonic SNPs to intronic, and listing 21 UTR SNPs, 
seven of which are included in the final SNP pool. No other designations of SNP-type changed.  
The remaining SNPs were chosen for redundancy purposes in the “redundant primary” 
category. These SNPs were chosen based on their LD value (r2≥0.80) with the primary SNPs, 
leading to eight additional SNPs. This step built redundancy into the design for several of the 
primary SNPs to be used in the event that one of the primary SNPs could not be genotyped.  
 After choosing the SNPs for the study, the list was submitted to Applied Biosystems, Inc. 
(ABI) SNPlex Genotyping System 48-plex Assay Design and Ordering System (accessed 
07/2007) in order to create the Oligo Pool Assay (OPA). The design system checked for a 
noncompetitive reaction, deleterious pooling, and small pooling within the proposed pool. A 
total of six designs were submitted before a combination of 48 SNPs cleared the algorithm as 
being able to function appropriately within one OPA pool. Primary SNP 
SNP8NRG243177/rs6994992 failed the algorithm in each design that was submitted due to small 
pooling, and thus could not be included in the final OPA. In addition, primary SNP rs32016134 
was excluded due to a genome error, as this is a mouse SNP, but was labeled as a human NRG1 
SNP associated with schizophrenia in Munafo et al. (2006). Finally, rs776365, rs1566778, 
rs2466084, and rs3735775 were excluded to reduce the size of the SNP pool to the required 48. 
These particular SNPs were chosen for exclusion because they were redundant for primary and 
haplotype SNPs that already had at least one redundant in the pool.  
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As seen in Tables 11 and Figure 1, the final design contained 21 primary, 19 haplotype, 4 
other, and 4 redundant primary SNPs.  
Table 11. Proposed List of SNPs
Genome 
Location (bp) Marker Type Category 
31593281 SNP8NRG221132 Upstream Primary 
31593682 SNP8NRG221533/rs35753505 Upstream Primary 
31595198 rs10096573 Upstream Redundant Primary 
31604412 rs4298458 Upstream Primary 
31613876 SNP8NRG241930 Intron Primary 
31619806 rs1081062 Intron Primary 
31653120 rs13274954 Intron Redundant Primary 
31693237 rs4566990 Intron Haplotype 
31760521 rs1354335 Intron Haplotype 
31764413 rs1354336 Intron Haplotype 
31798512 rs13256173 Intron Redundant Primary 
31799612 rs1354334 Intron Primary 
31817937 SNP8NRG444511/rs13268724 Intron Primary 
31822702 SNP8NRG449280 Intron Haplotype 
31836504 rs776401 Intron Haplotype 
31853301 rs1473438 Intron Primary 
31878179 rs776382 Intron Haplotype 
31899469 rs1481438 Intron Haplotype 
31902481 rs800501 Intron Haplotype 
31950557 rs1462893 Intron Haplotype 
32018532 rs10954821 Intron Haplotype 
32178170 rs726908 Intron Haplotype 
32184904 rs1481747 Intron Haplotype 
32501778 rs10954855 Intron Haplotype 
32545133 rs2439306 Intron Haplotype 
32562632 rs2466062 Intron Haplotype 
32572900 rs3924999 Exon (R/Q AA change) Primary 
32592113 rs5890668 Intron Primary 
32592302 rs6150532 Intron Primary 
32595233 rs2466060 Intron Haplotype 
32612634 rs2439272 Intron Primary 
32620351 rs6468121 Intron Primary 
32621168 rs2466044 Intron Redundant Primary 
32626691 rs2466058 Intron Primary 
32634458 rs2466049 Intron Primary 
32646823 rs723811 Intron Haplotype 
32665458 rs6988339 Intron Primary 
32667621 rs10691392 Intron Haplotype 
32671731 rs2975498 Intron Primary 
32680307 rs2919382 Intron Primary 
32692525 rs2976525 Intron Primary 
32702243 rs4262285 Intron Primary 
32704976 rs3735776 Intron Primary 
32727416 rs4512342 Intron Haplotype 
32733525 rs10503929 Exon (M/T AA change) Other 
32743929 rs6992642 Downstream Other 
32744370 rs3735781 Downstream Other 
32744399 rs3735782 Downstream Other 
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Figure 1. Line Diagram of NRG1 with SNP Locations 
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2.2.4  Genotyping Methods 
Blood was collected in ethylenediamine tetraacetic acid (EDTA) tubes and frozen at either -70°C 
or -140°C until bulk DNA extraction was performed. At that time, blood was thawed in a 47°C 
water bath and DNA was extracted according to the phenol-chloroform method. Quantification 
of DNA was then completed using the Invitrogen Quant-iT PicoGreen method (Chadwick et al., 
1996). After extraction and quantification, samples were transferred to 96-well plates to begin 
ABI’s SNPlex Genotyping method (SNPlex 3130xl, data collection v3). This system allowed 
simultaneous genotyping of 48 SNPs per well of DNA.  
2.2.4.1 Quality Control Procedures: Individual Analysis of DNA Samples. After the 
SNPlex procedure, data were uploaded into GeneMapper 4.0 software to assess the quality of 
results. Each DNA sample was assessed separately for low peaks, failure of the size standard, 
and failure of the sample. Individual analysis helped to control for procedural error and poor 
quality DNA samples. In addition, all participant samples with a peak intensity of less than 
100Rfu were excluded on a SNP-by-SNP basis, as this generally suggests that the sample’s peak 
at the given SNP was not high enough to genotype accurately. Any problem samples identified 
using the above methods were rerun in a “clean-up” stage using the procedures outlined above. 
Genotyping was attempted one final time on those samples that continued to be problematic 
during the initial clean-up stage using the original mainstock samples. Samples that failed initial 
genotyping and both clean-up stages were excluded from all of the subsequent analyses (N=40). 
Next, all samples that passed the quality control standards, but failed on ten or more individual 
SNPs, were excluded from analysis to control for poor sample quality, contamination, and/or 
procedural error (N=4). In addition, all participants with one or more Mendelian Errors (N=6), as 
assessed by PedCheck (O'Connell & Weeks, 1998), were excluded. One individual had 
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homozygous genotypes at every SNP, suggesting poor sample quality or procedural error, and 
was excluded. In addition, five samples failed the first analysis and a clean-up analysis using the 
plated DNA, but were missing mainstock vials and could not be run in a second clean-up stage. 
Finally, 78 samples collected at the PENN site were not plated at the PITT site at the time of 
analysis and could not be included. Overall, this resulted in the loss of 134 participants who were 
enrolled, completed the diagnostic and neuropsychological portions of the study, and whose 
DNA was collected, but who were not successfully genotyped for NRG1 SNPs.  
2.2.4.2 Quality Control Procedures: SNP-wise Analysis.
On the level of SNP performance, three SNPs (rs10691392, rs5890668, rs615032) were 
excluded for being insertion/deletion polymorphisms rather than true SNPs. In addition, one SNP 
(rs1481438) was excluded from analyses as, although it was listed as a NRG1 SNP by Munafo et 
al. (2006), it is actually located within a gene on chromosome six. Three SNPs (rs1481747, 
rs776382, rs800501) were also excluded for high failure rates (≥20%). One SNP 
(SNP8NRG449280) was monomorphic in the sample and was excluded. After removing these 
SNPs, the total SNP pool for analysis contained 40 SNPs (19 primary, 13 haplotype, 4 other, and 
4 redundant primary), as shown in Table 12. Every SNP was in Hardy-Weinberg Equilibrium, 
 After the analysis of individual 
DNA samples was complete, cluster analysis was used to determine genotyping outliers at the 
level of each individual SNP. These outliers were suggestive of either poor DNA quality or 
competition between primers at annealing sites during the reaction. Five SNPs (rs3735776, 
rs726908, rs3735781, rs2919382, and SNP8NRG241930) could not be clustered by 
GeneMapper, but were clustered by hand independently by three of the investigators (JLY, KP, 
and MET) and results were checked for fidelity.  
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except rs2919382 (p=0.0173), as calculated by SOLAR, with between 0% and 12.65% 
genotyping failure per SNP (mean failure = 1.09%, SD = 2.71).  
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Table 12. List of Successful SNPs 
SNP Location 
Major 
Allele 
Minor 
Allele 
Minor 
Allele 
Frequency 
HWE 
(p) Type Category 
Successful 
Genotyping 
Rate, N (% 
Failure) 
SNP8NRG221132 31593281 G A 0.1047 0.092 Upstream Primary 419 (0.00%) 
SNP8NRG221533 31593682 T C 0.3357 0.8267 Upstream Primary 415 (0.95%) 
rs10096573 31595198 T G 0.4248 0.8138 Upstream Redundant Primary 419 (0.00%) 
rs4298458 31604412 G C 0.4273 0.7365 Upstream Primary 419 (0.00%) 
SNP8NRG241930 31613876 G T 0.323 0.9984 Intron Primary 413 (1.43%) 
rs1081062 31619806 T C 0.2624 0.5541 Intron Primary 417 (0.48%) 
rs13274954 31653120 T A 0.2499 0.7163 Intron Redundant Primary 419 (0.00%) 
rs4566990 31693237 G A 0.3602 0.8488 Intron Haplotype 419 (0.00%) 
rs1354335 31760521 C G 0.1818 0.5845 Intron Haplotype 410 (2.15%) 
rs1354336 31764413 T C 0.2504 0.4461 Intron Haplotype 414 (1.19%) 
rs13256173 31798512 A G 0.1821 0.3825 Intron Redundant Primary 419 (0.00%) 
rs1354334 31799612 G T 0.3806 0.612 Intron Primary 419 (0.00%) 
SNP8NRG444511 31817937 T A 0.1821 0.3825 Intron Primary 419 (0.00%) 
rs776401 31836504 T C 0.3677 0.7222 Intron Haplotype 417 (0.48%) 
rs1473438 31853301 A G 0.3741 0.8179 Intron Primary 416 (0.72%) 
rs1462893 31950557 C G 0.2064 0.7706 Intron Haplotype 417 (0.48%) 
rs10954821 32018532 G A 0.3049 0.6254 Intron Haplotype 419 (0.00%) 
rs726908 32178170 A G 0.4833 0.4034 Intron Haplotype 416 (0.72%) 
rs10954855 32501778 T A 0.2292 0.6433 Intron Haplotype 419 (0.00%) 
rs2439306 32545133 G A 0.2172 0.7888 Intron Haplotype 397 (5.25%) 
rs2466062 32562632 A G 0.2714 0.1154 Intron Haplotype 418 (0.24%) 
rs3924999 32572900 C T 0.3857 0.8048 Exon (R/Q change) Primary 417 (0.48%) 
rs2466060 32595233 G A 0.4882 0.4585 Intron Haplotype 374 (10.74%) 
rs2439272 32612634 C T 0.44 0.5747 Intron Primary 418 (0.24%) 
rs6468121 32620351 G T 0.453 0.1228 Intron Primary 415 (0.95%) 
rs2466044 32621168 T C 0.0831 0.8241 Intron Redundant Primary 417 (0.48%) 
rs2466058 32626691 G A 0.0862 0.7073 Intron Primary 419 (0.00%) 
rs2466049 32634458 C T 0.0809 0.6305 Intron Primary 416 (0.72%) 
rs723811 32646823 T C 0.0883 0.8834 Intron Haplotype 419 (0.00%) 
rs6988339 32665458 A G 0.4153 0.8957 Intron Primary 419 (0.00%) 
rs2975498 32671731 A G 0.1794 0.1645 Intron Primary 419 (0.00%) 
rs2919382 32680307 T C 0.167 0.0173 Intron Primary 419 (0.00%) 
rs2976525 32692525 A C 0.0879 0.8411 Intron Primary 419 (0.00%) 
rs4262285 32702243 C T 0.043 0.4804 Intron Primary 419 (0.00%) 
rs3735776 32704976 C A 0.1553 0.9587 Intron Primary 366 (12.65%) 
rs4512342 32727416 T G 0.1037 0.7385 Intron Haplotype 417 (0.48%) 
rs10503929 32733525 T C 0.1814 0.5694 Exon (M/T change) Other 419 (0.00%) 
rs6992642 32743929 T C 0.4059 0.6583 Downstream Other 419 (0.00%) 
rs3735781 32744370 A G 0.418 0.5275 Downstream Other 416 (0.72%) 
rs3735782 32744399 C A 0.4827 0.1678 Downstream Other 418 (0.24%) 
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The LD patterns of the final SNP set, as measured by rho in SOLAR, can be seen in 
Figure 2. As expected, most of the SNPs were in very low LD with each other, with the 
exception of a few high LD SNPs that were built into the pool for redundancy. 
 
 
Figure 2. Linkage Disequilibrium (rho) Values 
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rs3735782 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.3 0.2 0.3 0.4 0.2 0.2 0.2 0.2 0.4 0.1 0.0 0.2 0.2 0.1 0.3 0.5 0.8 0.8
rs3735781 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.3 0.3 0.4 0.3 0.2 0.2 0.2 0.3 0.5 0.1 0.0 0.2 0.2 0.4 0.3 0.4 0.1 1.0
rs6992642 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.4 0.3 0.2 0.2 0.2 0.3 0.5 0.1 0.0 0.2 0.2 0.4 0.3 0.4 0.9
rs10503929 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.2 0.2 0.2 0.2 0.2 0.8
rs4512342 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.2 0.2 0.1 0.6 0.6 0.6 0.1 0.2 0.0 0.0 0.1 0.3 0.8 0.7
rs3735776 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.3 0.3 0.0 0.6 0.6 0.6 0.2 0.3 0.2 0.1 0.2 0.5 0.5-0.6
rs4262285 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.3 0.2 0.4 0.2 0.2 0.3-0.4
rs2976525 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.3 0.3 0.0 0.0 0.0 0.1 0.3 0.7 0.8 0.1-0.2
rs2919382 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.2 0.4 0.4 0.1 0.1 0.1 0.6 0.4 0.9 0
rs2975498 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.1 0.0 0.3 0.4 0.4 0.1 0.1 0.1 0.7 0.4
rs6988339 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.4 0.7 0.6 0.2 0.2 0.2 0.3
rs723811 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.2 0.2 0.2 0.3 0.3 0.1 0.1 0.1
rs2466049 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.2 0.0 0.1 0.2 0.3 0.2
rs2466058 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.2 0.3 0.2
rs2466044 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.2 0.0 0.1 0.2 0.3 0.2
rs6468121 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.5 0.8
rs2439272 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.0 0.1 0.2 0.6
rs2466060 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.2 0.2 0.0 0.1 0.5
rs3924999 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.2 0.0 0.2 0.0 0.0 0.2 0.1 0.1 0.0 0.3 0.0 0.1
rs2466062 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3
rs2439306 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0
rs10954855 0.1 0.0 0.0 0.0 0.1 0.2 0.2 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1
rs726908 0.0 0.0 0.1 0.1 0.1 0.3 0.3 0.1 0.3 0.3 0.3 0.1 0.3 0.0 0.0 0.1 0.1
rs10954821 0.2 0.1 0.0 0.0 0.2 0.2 0.3 0.2 0.1 0.2 0.0 0.2 0.0 0.0 0.3 0.6
rs1462893 0.1 0.1 0.0 0.0 0.2 0.2 0.2 0.1 0.2 0.0 0.2 0.1 0.2 0.1 0.1
rs1473438 0.3 0.2 0.0 0.0 0.2 0.2 0.2 0.6 0.4 0.7 0.3 0.6 0.3 1.0
rs776401 0.2 0.2 0.0 0.0 0.2 0.2 0.2 0.6 0.3 0.7 0.3 0.6 0.3
SNP8NRG444511 0.1 0.0 0.1 0.1 0.0 0.6 0.5 0.4 0.3 0.4
rs1354334 0.2 0.3 0.2 0.2 0.0 0.1 0.1 0.9 0.4 0.4 0.4
rs13256173 0.1 0.0 0.1 0.1 0.0 0.6 0.5 0.4 0.3
rs1354336 0.4 0.2 0.0 0.0 0.2 0.4 0.4 0.5 0.3
rs1354335 0.1 0.0 0.1 0.1 0.0 0.6 0.5 0.4
rs4566990 0.2 0.3 0.2 0.2 0.1 0.1 0.1
rs13274954 0.1 0.0 0.1 0.1 0.2
rs1081062 0.1 0.0 0.1 0.1 0.2
SNP8NRG241930 0.5 0.6 0.4 0.4
rs4298458 0.3 0.8
rs10096573 0.3 0.8
SNP8NRG221533 0.3
SNP8NRG221132
LEGEND
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3.0  RESULTS 
3.1  DEMOGRAPHIC COMPARISONS 
Comparisons between the final proband and final control samples revealed that there were 
significantly more females in the control sample (t=-2.58, df=27.96, p=0.016) and that controls 
had significantly more personal education than probands in this sample (t=-5.03, df=218, 
p=0.000; see Table 4). In addition, both age and paternal education showed trends towards 
significance, with controls being older (t=-1.99, df=43.33, p=0.052) and having more paternal 
education (t=-1.91, df=211, p=0.058) than probands.  
Comparisons between the final relative and final control samples revealed that controls 
had significantly more personal (t=-7.85, df=480.3, p=0.000), maternal (t=-5.09, df=520, 
p=0.000), and paternal (t=-4.79, df=509, p=0.000) education than relatives, but were not 
significantly different on age or sex.  
When the final sample was broken down into affected, unaffected, and control 
participants (Table 6), comparisons between the affected and control participants showed 
significantly more females in the control sample (t=-3.43, df=96.45, p=0.001) and significantly 
more personal education for controls than affected participants in this sample (t=-5.91, df=255, 
p=0.000). In addition, control participants had greater paternal education than affected 
participants (t=-1.93, df=236, p=0.55).  
Comparisons between unaffected pedigree members and controls found that control 
participants had significantly more personal (t=-6.16, df=558, p=0.000), maternal (t=-5.14, 
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df=491, p=0.000), and paternal (t=-5.17, df=485, p=0.000) education than unaffected 
participants, but were not significantly different on age or sex. 
 
3.2  NEUROCOGNITIVE BATTERY 
The cognitive data for the final control and pedigree samples were checked for outliers by box 
plot analysis collapsed over group. Two domain scores had one extreme outlier each. These 
outliers were each more than six standard deviations from the next most extreme score, and were 
Winsorized to reduce the amount of effect the data point would exert on the distribution as a 
whole. Next, all participants’ domain scores were converted to z-scores, with the present study’s 
final control group data serving as the standard. As seen in Tables 13-15, this standardization 
resulted in the control group’s mean being zero (SD=1) for every domain.  As expected, there 
was a significant difference in performance (as measured by efficiency) between affected 
participants and controls for every CNB domain (p=0.000). The performance of unaffected 
relatives was also poorer than controls for every domain, except for attention and abstraction and 
mental flexibility’s speed scores.  In addition, most domains had significant skew for all groups 
on all domain categories (efficiency, accuracy, and speed).  
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Table 13. Neurocognitive Battery Descriptive Data (Efficiency) 
 
 
 
Table 14. Neurocognitive Battery Descriptive Data (Accuracy) 
 
Affected Relatives & Probands Unaffected Relatives Controls 
 
N Mean 
Std. 
Deviation Skewness N Mean 
Std. 
Deviation Skewness N Mean 
Std. 
Deviation Skewness 
Abstraction & 
Mental 
Flexibility 55 -1.23 1.2174 0.806 348 -0.17 1.1106 -0.577 199 0 1 -0.9255 
Attention 55 -1.74 2.1278 -1.609 344 -0.39 1.443 -2.288 159 0 1 -2.9889 
Verbal Memory 58 -1.26 1.5838 -0.642 360 -0.31 1.1803 -1.125 195 0 1 -0.6453 
Facial Memory 58 -0.97 1.00156 -0.086 360 -0.23 1.01552 -0.69 188 0 1 -0.6646 
Spatial 
Memory 57 -0.81 1.1216 0.017 359 -0.15 0.9749 -0.166 199 0 1 -0.1457 
Spatial 
Processing 53 -1.16 1.633 -0.436 353 -0.19 1.1891 -0.936 198 0 1 -0.6003 
Sensorimotor 
Dexterity 54 -1.18 2.4003 -2.124 345 -0.09 1.6107 -7.056 191 0 1 -4.8296 
Emotional 
Processing 57 -1.53 1.4126 -0.272 359 -0.26 1.1557 -0.845 194 0 1 -1.434 
Standard error of the skewness for affected relatives and probands ranged between  0.3140-0.3270; SE for unaffected relatives ranged 
between 0.1290-0.1310; SE for controls ranged between 0.1723-0.1925.   
N Mean
Std. 
Deviation Skew ness N Mean
Std. 
Deviation Skew ness N Mean
Std. 
Deviation Skew ness
Abstraction & 
Mental Flexibility 55 -1.227 1.1671 0.846 348 -0.169 1.1077 -0.515 199 0 1 -0.8292
Attention 55 -1.805 2.0679 -1.426 344 -0.344 1.4281 -2.04 159 0 1 -2.3109
Verbal Memory 58 -1.209 1.3732 -0.358 360 -0.331 1.0963 -0.802 185 0 1 -0.4262
Facial Memory 58 -0.924 0.9303 -0.04 360 -0.257 1.0034 -0.605 188 0 1 -0.3713
Spatial Memory 57 -0.789 1.0051 0.073 359 -0.175 0.9539 -0.074 199 0 1 -0.097
Spatial 
Processing 52 -1.125 1.4523 -0.346 353 -0.211 1.1041 -0.874 195 0 1 -0.5398
Sensorimotor 
Dexterity 54 -1.397 1.7499 -1.234 345 -0.235 1.2738 -4.136 191 0 1 -2.4976
Emotional 
Processing 57 -1.554 1.2852 -0.136 359 -0.29 1.1571 -0.748 194 0 1 -0.8743
Standard error of the skew ness for affected relatives and probands ranged betw een  0.3140-0.3250; SE for unaffected relatives 
ranged betw een 0.1290-0.1310; SE for controls ranged betw een 0.1723-0.1925. 
Affected Relatives & Probands Unaffected Relatives Controls
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Table 15. Neurocognitive Battery Descriptive Data (Speed) 
 
Affected Relatives & Probands Unaffected Relatives Controls 
 
N Mean 
Std. 
Deviation Skewness N Mean 
Std. 
Deviation Skewness N Mean 
Std. 
Deviation Skewness 
Abstraction & 
Mental 
Flexibility 55 -0.47 0.9704 -1.029 348 0.076 0.8953 -2.726 199 0 1 -3.0384 
Attention 55 -0.92 1.2665 -0.84 344 0.031 1.0084 -0.75 159 0 1 -0.7978 
Verbal 
Memory 58 -0.84 1.7162 -2.575 360 -0.32 1.51 -2.728 195 0 1 -1.3268 
Facial 
Memory 58 -0.24 1.0668 -1.909 360 -0.32 1.6285 -3.403 188 0 1 -1.5394 
Spatial 
Memory 57 -0.21 1.2636 -2.455 359 -0.17 1.1166 -2.004 199 0 1 -2.2258 
Spatial 
Processing 52 -1.4 2.7318 -2.555 353 -0.21 1.3287 -3.028 198 0 1 -1.6117 
Sensorimotor 
Dexterity 54 -1.37 1.4406 -0.414 345 -0.32 1.2955 -2.581 191 0 1 -2.5124 
Emotional 
Processing 57 -0.4 1.1085 -1.511 359 -0.11 1.1577 -3.375 194 0 1 -1.4521 
Standard error of the skewness for affected relatives and probands ranged between  0.3140-0.3300; SE for unaffected relatives ranged 
between 0.1290-0.1310; SE for controls ranged between 0.1723-0.1925.   
 
 
3.2.1  Heritability (h2) 
Heritability was estimated in SOLAR for each cognitive domain. Potential covariates included in 
the polygenic model for heritability estimates and associations included: age, sex, age2, age-by-
sex, age2-by-sex, and handedness. Each covariate was screened separately and retained in the 
model if it was significant at p<0.10. The retained covariates and heritability estimates for every 
cognitive domain are shown in Table 16, with values closely matching the heritability levels 
found by Gur et al. (2007). All of the heritability estimates were significant and ranged from 0.23 
to 0.57 (efficiency), 0.24-0.52 (accuracy), and 0.07-0.54 (speed), indicating the importance of 
total genetic variation for all of the cognitive domains. 
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Table 16. Heritability Estimates for CNB Domains (Accuracy, Time, & Efficiency) in the Final 
Sample 
 
  
Abstraction 
& Mental 
Flexibility 
Attention Verbal Memory 
Facial 
Memory 
Spatial 
Memory 
Spatial 
Processing 
Sensorimotor 
Dexterity 
Emotional 
Processing 
 
N 402 398 417 417 415 405 398 415 
Ef
fic
ie
nc
y 
h2 0.3737 0.2961* 0.5327* 0.3963 0.4428 0.5682 0.2324* 0.4517 
p-value 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0002 0.0000 
Covariates age, sex, age2 
age, age2, 
age2*sex age, sex 
age, sex, 
age2 age 
age, sex, 
age2, 
age2*sex, 
handedness 
age age, sex, age2 
A
cc
ur
ac
y h
2 0.3441 0.2406* 0.4906* 0.3805 0.4145 0.5176* 
Not 
applicable^ 
0.4273* 
p-value 0.0000 0.0001 0.0000 0.0000 0.0000 0.0000 0.0000 
Covariates age, sex, age2 
age, age2, 
age2*sex age, sex 
age, sex, 
age2 age 
sex, 
age*sex 
age, sex, 
age2 
Sp
ee
d 
h2 0.1311* 0.5397* 0.1896* 0.3506* 0.1040* 0.1127* 0.2477* 0.0700* 
p-value 0.0201 0.0000 0.0103 0.0000 0.0655 0.0970 0.0008 0.1725 
Covariates age, age2 age, age2 age, sex age, age2 age, sex, handedness 
age, sex, 
age2, 
age2*sex 
age age, age2 
 
 
3.3  ASSOCIATIONS BETWEEN CNB DOMAINS AND NRG1 SNPS 
SNPs were tested for association with cognitive variation by quantitative trait linkage 
disequilibrium (QTLD), unless there was evidence of stratification of the trait. In this case, 
quantitative transmission disequilibrium (QTDT) was used to measure associations. QTLD is a 
more powerful measure of association than QTDT, but is less robust to population stratification 
(Havill, Dyer, Richardson, Mahaney, & Blangero, 2005). QTDT is more conservative, but more 
appropriate when stratification is present.  
 In each analysis, at least one association was significant for QTDT while having 
significant (p≤0.05) stratification , as defined as βbetween ≠ βwithin (Fulker, Cherny, Sham, & 
Hewitt, 1999). In addition, most associations with significant stratification had opposite signed 
beta weights for the within- and between-family SNP regression coefficients, indicating that the 
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association was one direction within families and the opposite direction between families. Such 
associations are noted below.  
 
3.3.1  Associations in the Final Sample 
Twenty-two significant (p≤0.05) associations between the efficiency measures of  each CNB 
domain and NRG1 SNPs were detected in the final sample, which consisted of both affected and 
unaffected participants. As seen in Table 17, every domain, except spatial memory, had at least 
one significant association with a NRG1 SNP (range: 0-10 associations per domain; mean of 
2.75). These associations encompassed 13 SNPs (range: 0-4 associations per SNP; mean of 
0.55), and were spread across the gene, including UTR’s, introns, and exons. The domain of 
attention had the highest number of significant associations (n=10) and the largest number of 
highly significant (p≤0.01) associations (n=3). All associations in this sample were measured by 
QTLD, except for nine total QTDT associations in the domains of attention (rs1354335, 
rs1354336, rs13256173, SNP8NRG444511/rs13268724, rs776401, rs1473438, and rs10503929), 
facial memory (rs6468121), and verbal memory (rs10503929), due to significant levels of 
stratification. Eight of the nine QTDT associations had opposite between- and within-family beta 
weights; the QTDT association between attention and rs10503929 had negative between and 
within-family betas.  
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Table 17. Significant Associations (p-values; p≤0.05) by SNP and Efficiency Domain in the 
Final Sample 
SNP 
Abstraction 
& Mental 
Flexibility Attention 
Verbal 
Memory 
Facial 
Memory 
Spatial 
Memory 
Spatial 
Processing 
Sensorimotor 
Dexterity 
Emotional 
Processing 
SNP8NRG221132                 
SNP8NRG221533                 
rs10096573                 
rs4298458                 
SNP8NRG241930                 
rs1081062                 
rs13274954                 
rs4566990                 
rs1354335   0.0175*^             
rs1354336   0.0021*^             
rs13256173   0.0291*^             
rs1354334                 
SNP8NRG444511   0.0291*^             
rs776401   0.0440*^             
rs1473438   0.0324*^             
rs1462893                 
rs10954821                 
rs726908                 
rs10954855     0.0127           
rs2439306     0.0411           
rs2466062                 
rs3924999   0.031           0.0235 
rs2466060   0.0044           0.0262 
rs2439272   0.0152   0.0306   0.0458   0.0356 
rs6468121       0.0485*^       0.0502 
rs2466044                 
rs2466058                 
rs2466049                 
rs723811                 
rs6988339                 
rs2975498                 
rs2919382                 
rs2976525                 
rs4262285                 
rs3735776                 
rs4512342                 
rs10503929 0.0318 0.0094* 0.0287*^       0.047   
rs6992642                 
rs3735781                 
rs3735782                 
See Table 16 for covariates included in the association model for each cognitive domain. 
Associations significant after Bonferroni correction (p≤0.0051) are bolded.  
*All p-values reflect QTLD results, except the following QTDT results in the domain of attention (rs1354335, rs1354336, rs13256173, 
SNP8NRG444511, rs776401, rs1473438, and rs10503929), facial memory (rs6468121), and verbal memory (rs10503929). 
^Associations with significant stratification and opposite signs for between- and within-family beta weights 
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3.3.1.1 Determining the Number of Effective SNPs.
Pair-
wise 
LD 
  As previously mentioned, several 
“redundant” SNPs in high LD with “primary” ones were included in the genotyping pool. These 
redundant SNPs were included in the association analyses and support the genotyping and 
association results of the primary SNPs. As shown in Table 18, the results of the redundant and 
primary SNPs are highly concordant, confirming our genotyping and association findings.  
 
Table 18. Association Findings between SNPs in High LD 
SNP 
Abstraction 
& Mental 
Flexibility Attention 
Verbal 
Memory 
Facial 
Memory 
Spatial 
Memory 
Spatial 
Processing 
Sensorimotor 
Dexterity 
Emotional 
Processing 
LD = 
1.0 
rs776401   0.0440*             
rs1473438   0.0324*             
LD = 
0.99 
rs10096573                 
rs4298458                 
LD = 
0.95 
rs1081062                 
rs13274954                 
LD = 
0.98 
rs1354335   0.0175*             
SNP8NRG444511   0.0291*             
LD = 
1.0 
rs13256173   0.0291*             
SNP8NRG444511   0.0291*             
LD = 
0.98 
rs13256173   0.0291*             
rs1354335   0.0175*             
LD = 
0.98 
rs2466044                 
rs2466058                 
LD = 
0.99 
rs2466058                 
rs2466049                 
LD = 
0.99 
rs2466044                 
rs2466049                 
LD = 
0.99 
rs6992642                 
rs3735781                 
*Significant stratification 
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To estimate the number of effective SNPs needed to capture the genetic heterogeneity 
among SNPs in the pool given the LD structure of the primer set, and to control the alpha error 
rate, p-values adjusted for correlated tests (p_ACT) (Conneely & Boehnke, 2007) were 
computed using the R-program. This analysis revealed that only 24.753 of the 40 final SNPs 
were necessary to explain the genetic variation in the final sample. Genotype information from 
37 unrelated individuals in the final sample and 52 HapMap CEPH founders was used to 
estimate the number of effective SNPs. The combination of individuals from the current study 
and CEPH participants was used to raise the sample size to ensure the reliability of the results of 
the test. Individuals from the current study were chosen by the following method: if both parents 
of the index proband were in the final study, those individuals were included in the effective 
tests. If one or both parents were not in the final sample, then other individuals were chosen from 
the pedigree to represent the maternal and paternal sides of the family tree, working backwards 
from the proband. For example, if the father was not in the final sample, then the father’s mother 
or father was used. If one of those individuals was not in the final sample, a sibling of the father 
was used. If a sibling was not available, then a child of the sibling was used.  
Next the associations in Table 17 were corrected for multiple comparisons by using a 
Bonferroni adjustment (αB = αFW /C, where αFW is the familywise error rate (1-(1- α)C) and C is 
the number of comparisions; Keppel & Wickens, 2004) for comparisons between eight domains 
and 24.753 SNPs (C = 8*24.753 = 198.024), as suggested by the p_ACT results. This led to a 
new alpha level threshold of 0.0051. Using this alpha level, two associations remained 
significant: attention and rs1354336 (p=0.0021; QTDT), attention and rs2466060 (p=0.0044; 
QTLD).  
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3.3.1.2 Performance by Genotype.  Performance by genotype, as measured by the within-
family beta weights, for each significant association can be seen in Table 19. The minor allele 
conferred advantage in cognitive performance in 14 associations, while it conferred a detriment 
in eight associations. Effect sizes, as measured by the within-family beta weight, ranged between 
0.1569 and 0.5169 for those associations significant in the direction of the minor allele. This 
indicated that each copy of the minor allele was associated with an increase in cognitive 
performance on the specific task by between 0.1569 and 0.5169 standard deviations. The 
absolute values of the effect sizes in those associations significant in the opposite direction  
ranged from 0.177 to 0.5691, indicating a decrease in performance by between 0.177 to 0.5691 
standard deviations per copy of the minor allele.  
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Table 19. Significant Efficiency Associations in the Final Sample (by Genotype) 
SNP Domain Major Allele 
Minor 
Allele 
Beta 
within* 
Beta 
between* 
rs1354335 Attention^ C G 0.5169 -0.384 
rs1354336 Attention^ T C -0.5691 0.2479 
rs13256173 Attention^ A G 0.4601 -0.3559 
SNP8NRG444511 Attention^ T A 0.4601 -0.3559 
rs776401 Attention^ T C -0.3614 0.0399 
rs1473438 Attention^ A G -0.3897 0.0451 
rs10954855 Verbal Memory T A 0.3125 0.05 
rs2439306 Verbal Memory G A 0.2296 0.267 
rs3924999 
Attention C T 0.3207 0.0703 
Emotional 
Processing C T 0.2769 0.132 
rs2466060 
Attention G A 0.4221 -0.0275 
Emotional 
Processing G A 0.1569 0.0732 
rs2439272 
Attention C T 0.2641 -0.0902 
Facial Memory C T 0.2329 -0.0816 
Spatial Processing C T 0.2159 -0.1163 
Emotional 
Processing C T 0.2219 -0.0306 
rs6468121 
Facial Memory^ G T -0.2751 0.0682 
Emotional 
Processing G T -0.2528 -0.0431 
rs10503929 
Abstraction & 
Mental Flexibility T C -0.3942 0.0364 
Attention^ T C -0.556 -0.0323 
Verbal Memory^ T C -0.4035 0.1936 
Sensorimotor 
Dexterity T C -0.177 -0.0421 
*A positive value indicates that the minor allele confers a benefit, while a negative beta weight 
value indicates that the minor allele confers a detriment to cognitive performance. 
^ Significant stratification 
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3.3.1.3 The Role of Education within the Associations.  In order to assess the role of 
education level in the association between NRG1 SNPs and cognitive function, education was 
entered as a covariate for each cognitive domain (see Table 20). The models were re-estimated, 
including the previous covariates (age, sex, age2, age-by-sex, age2-by-sex, and handedness), as 
well as education. Again, all covariates with p<0.10 were retained in the model. Fourteen 
significant associations were found in this analysis. Every domain had at least one significant 
association with a NRG1 SNP (range: 0-8 associations per domain; mean of 1.75), except spatial 
memory, spatial processing, and emotional processing. These associations included 11 SNPs 
(range: 0-2 associations per SNP; mean of 0.350) and were spread across the gene. All 
associations in this analysis were estimated by QTLD, except for three QTDT associations in the 
domain of attention. All three QTDT associations had opposite between- and within-family beta 
weights. 
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Table 20. Significant Associations (p-values; p≤0.05) by SNP and Efficiency Domain including 
Education as a Covariate 
 
SNP 
Abstraction 
& Mental 
Flexibility Attention 
Verbal 
Memory 
Facial 
Memory 
Spatial 
Memory 
Spatial 
Processing 
Sensorimotor 
Dexterity 
Emotional 
Processing 
SNP8NRG221132                 
SNP8NRG221533                 
rs10096573                 
rs4298458                 
SNP8NRG241930                 
rs1081062                 
rs13274954                 
rs4566990                 
rs1354335   0.0332*^             
rs1354336   0.0030*^             
rs13256173                 
rs1354334                 
SNP8NRG444511                 
rs776401             0.0307   
rs1473438   0.0555*^         0.0231   
rs1462893                 
rs10954821                 
rs726908                 
rs10954855     0.0338           
rs2439306                 
rs2466062                 
rs3924999                 
rs2466060   0.0077             
rs2439272   0.0233   0.0436         
rs6468121                 
rs2466044                 
rs2466058                 
rs2466049                 
rs723811                 
rs6988339       0.0457         
rs2975498                 
rs2919382                 
rs2976525                 
rs4262285                 
rs3735776                 
rs4512342                 
rs10503929 0.009 0.0079             
rs6992642   0.0377             
rs3735781   0.0477             
rs3735782                 
All associations were re-estimated, including the following covariates: age, sex, age2, age-by-sex, age2-by-sex, handedness, and 
education. All covariates with p<0.10 were retained in the model 
Associations significant after Bonferroni correction (p≤0.0051) are bolded.  
Shaded cells correspond to significant associations in the final sample when education was not included as a covariate (see Table 
17) 
*QTDT results reported due to significant trait stratification.  
^Associations with significant stratification and opposite signs for between- and within-family beta weights 
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Only eight associations in this analysis were also significant in the total final sample 
when education was not included as a potential covariate, as shown in Table 20, suggesting that 
variance in education levels may account for some of the relationship between NRG1 and 
cognitive functioning.  
Furthermore, associations using education as the trait with the original covariate set 
revealed two significant associations with individual SNPs, including: rs1081062 (p=0.0063; 
QTLD) and rs3924999 (p=0.0350; QTDT). 
3.3.1.4 Associations with Accuracy & Speed.  NRG1 SNPs were then checked for 
association using the components of efficiency (e.g., accuracy and speed). As seen in Table 21, 
there were 21 significant associations found between NRG1 SNPs and accuracy over the seven 
cognitive domains. Sensorimotor dexterity accuracy could not be examined due to low variance 
in performance. Every domain, except spatial memory, had at least one significant association 
with an individual SNP (range: 0-8 associations per domain; mean of 3.000). These associations 
encompassed 12 SNPs (range: 0-4 associations per SNP; mean of 0.525) across the gene. All 
associations in this analysis were measured by QTLD, except for eight associations total across 
the domains of attention, verbal memory, and spatial processing. All eight QTDT findings were 
of opposite beta weight signs, except the association between attention and rs10503929. When 
compared to the associations found in the total final sample, 16 associations remained 
significant, while five new associations were found, and five previous associations were lost. 
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Table 21. Significant Associations (p-values; p≤0.05) by SNP and Accuracy Domain  
SNP 
Abstraction 
& Mental 
Flexibility Attention 
Verbal 
Memory 
Facial 
Memory 
Spatial 
Memory 
Spatial 
Processing 
Sensorimotor 
Dexterity 
Emotional 
Processing 
SNP8NRG221132     0.0309       NA   
SNP8NRG221533 0.0497           NA   
rs10096573             NA   
rs4298458             NA   
SNP8NRG241930             NA   
rs1081062             NA   
rs13274954             NA   
rs4566990             NA   
rs1354335   0.0340*^         NA   
rs1354336   0.0034*^         NA   
rs13256173   0.0437*^         NA   
rs1354334             NA   
SNP8NRG444511   0.0437*^         NA   
rs776401             NA   
rs1473438             NA   
rs1462893             NA   
rs10954821             NA   
rs726908             NA   
rs10954855     0.0082 0.0448     NA   
rs2439306     0.02       NA   
rs2466062             NA   
rs3924999   0.0334         NA 0.0126 
rs2466060   0.0438*^       0.0446 NA 0.0181 
rs2439272   0.0284       0.0171 NA 0.0432 
rs6468121             NA   
rs2466044             NA   
rs2466058             NA   
rs2466049             NA   
rs723811             NA   
rs6988339             NA   
rs2975498             NA   
rs2919382             NA   
rs2976525             NA   
rs4262285             NA   
rs3735776             NA   
rs4512342             NA   
rs10503929 0.0324 0.0130* 0.0318*^     0.0180*^ NA   
rs6992642             NA   
rs3735781             NA   
rs3735782             NA   
All associations were re-estimated, including the following covariates: age, sex, age2, age-by-sex, age2-by-sex, and handedness.  
All covariates with p<0.10 were retained in the model 
     NA: Accuracy in the sensorimotor dexterity domain could not be estimated due to low variance in the variable. 
 Associations significant after Bonferroni correction (p≤0.0051) are bolded. 
   Shaded cells correspond to significant associations in the final sample when education was not included as a covariate (Table 17) 
*QTDT results reported due to significant trait stratification. 
     ^Associations with significant stratification and opposite signs for between- and within-family beta weights 
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As seen in Table 22, there were 17 significant associations found between NRG1 SNPs 
and speed over the eight cognitive domains. Every domain, except emotional processing, had at 
least one significant association with an individual SNP (range: 0-6 associations per domain; 
mean of 2.125). These associations encompassed 14 SNPs (range: 0-3 associations per SNP; 
mean of 0.425) across the gene. All associations in this analysis were measured by QTLD, 
except for seven associations total in the domains of attention and spatial memory. All QTDT 
findings were of opposite beta weight signs. When compared to the associations found in the 
total final sample, five associations remained significant, while 12 new associations were found 
and 17 previous associations were lost. 
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Table 22. Significant Associations (p-values; p≤0.05) by SNP and Speed Domain  
SNP 
Abstraction 
& Mental 
Flexibility Attention 
Verbal 
Memory 
Facial 
Memory 
Spatial 
Memory 
Spatial 
Processing 
Sensorimotor 
Dexterity 
Emotional 
Processing 
SNP8NRG221132                 
SNP8NRG221533                 
rs10096573                 
rs4298458                 
SNP8NRG241930                 
rs1081062                 
rs13274954     0.0349           
rs4566990                 
rs1354335   0.0362*^             
rs1354336 0.051 0.0328*^             
rs13256173   0.0427*^             
rs1354334                 
SNP8NRG444511   0.0427*^             
rs776401             0.0505   
rs1473438 0.0509               
rs1462893                 
rs10954821 0.0165               
rs726908         0.0335       
rs10954855                 
rs2439306                 
rs2466062   0.0032*^             
rs3924999                 
rs2466060                 
rs2439272                 
rs6468121 0.0411               
rs2466044                 
rs2466058                 
rs2466049                 
rs723811                 
rs6988339                 
rs2975498                 
rs2919382                 
rs2976525                 
rs4262285           0.0409     
rs3735776       0.0248 0.0027*^ 0.0379     
rs4512342                 
rs10503929   0.0288*^             
rs6992642                 
rs3735781                 
rs3735782                 
All associations were re-estimated, including the following covariates: age, sex, age2, age-by-sex, age2-by-sex, and handedness.  
All covariates with p<0.10 were retained in the model 
     Associations significant after Bonferroni correction (p≤0.0051) are bolded. 
   Shaded cells correspond to significant associations in the final sample when education was not included as a covariate (Table 17) 
*QTDT results reported due to significant trait stratification. 
    ^Associations with significant stratification and opposite signs for between- and within-family beta weights 
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When comparing the accuracy and speed results with the associations with efficiency, 
most (72.72%) of the SNPs with significant efficiency associations also had significant 
associations with accuracy. Only a few (22.72%) had significant associations with both accuracy 
and speed, and no SNPs were significantly associated with speed alone. Finally, six efficiency 
associations had no significant associations with either accuracy or speed, suggesting that the 
combination of the two components drove the association findings.  
 
3.3.2  Associations in the Unaffected Sample 
In order to understand better the associations between NRG1 and cognition in the context of 
schizophrenia, associations were re-run in progressively “cleaner” samples. As previously 
mentioned, there were 361 participants in the final sample who did not meet criteria for either 
schizophrenia or schizoaffective disorder-depressed, creating an unaffected sub-sample within 
the final sample. QTLD and QTDT were estimated for this subsample using the methods 
outlined above for model estimation and covariate screening. As seen in Table 23, 23 significant 
associations were found in this subsample. Every domain, except spatial processing, had at least 
one significant association with a NRG1 SNP (range: 0-7 associations per domain; mean of 
2.875). These associations encompassed 13 SNPs (range: 0-3 associations per SNP; mean of 
0.575), and were spread across the gene, including UTR’s, introns, and exons. All associations in 
this sample were measured by QTLD, except for 13 QTDT associations total across the domains 
of abstraction and mental flexibility; attention; verbal, facial, and spatial memory; and 
sensorimotor dexterity. All QTDT associations were of opposite beta weight directions. 
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Table 23. Significant Associations (p-values) by SNP and Efficiency Domain for the Unaffected 
Sub-sample of the Final Sample 
SNP 
Abstraction 
& Mental 
Flexibility Attention 
Verbal 
Memory 
Facial 
Memory 
Spatial 
Memory 
Spatial 
Processing 
Sensorimotor 
Dexterity 
Emotional 
Processing 
SNP8NRG221132     0.0502   0.0497*^       
SNP8NRG221533                 
rs10096573                 
rs4298458                 
SNP8NRG241930                 
rs1081062   0.0299*^             
rs13274954                 
rs4566990                 
rs1354335   0.0059*^         0.0423*^   
rs1354336   0.0044*^             
rs13256173 0.0511*^ 0.0212*^         0.0431*^   
rs1354334                 
SNP8NRG444511 0.0511*^ 0.0212*^         0.0431*^   
rs776401                 
rs1473438                 
rs1462893       0.0211         
rs10954821                 
rs726908                 
rs10954855     0.0433 0.048         
rs2439306                 
rs2466062                 
rs3924999               0.0251 
rs2466060   0.0077           0.0168 
rs2439272   0.0404   0.0185         
rs6468121       0.0341*^         
rs2466044                 
rs2466058                 
rs2466049                 
rs723811                 
rs6988339                 
rs2975498                 
rs2919382                 
rs2976525                 
rs4262285                 
rs3735776                 
rs4512342                 
rs10503929 0.0534   0.0514*^           
rs6992642                 
rs3735781                 
rs3735782                 
Associations significant after Bonferroni correction (p≤0.0051) are bolded.  
Shaded cells correspond to significant associations in the final sample when education was not a covariate (Table 17) 
*QTDT results reported due to significant trait stratification. 
^Associations with significant stratification and opposite signs for between- and within-family beta weights 
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When compared to the associations found in the total final sample, thirteen associations 
remained significant, while ten new associations were found in this sample and nine previous 
associations were lost. When these results were adjusted by Bonferroni correction, as described 
above, one association remained significant: attention and rs1354336 (p=0.0044; QTDT). This 
association was also significant in the total final sample after Bonferroni correction.  
 
3.3.3  Associations in the “No Diagnosis” Sample 
Finally, associations were estimated in the sub-sample of individuals who had no diagnosis on 
the DIGS (N=178) using the methods described above. As seen in Table 24, 25 associations were 
found in this sample. Every domain had at least one significant association with a NRG1 SNP 
(range: 1-7 associations per domain; mean of 3.125). These associations encompassed 16 SNPs 
(range: 0-4 associations per SNP; mean of 0.625), and were spread across the gene. All 
associations in this sample were measured by QTLD, except for six QTDT associations total 
across the domains of attention; facial and spatial memory; and spatial processing. Four of the 
six QTDT associations had opposite signed beta weights. The associations between spatial 
memory and SNPs rs1081062 and rs13274954 had positive values for between- and within- 
family betas.  
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Table 24. Significant Associations (p-values) by SNP and Efficiency Domain for the No 
Diagnosis Sub-sample of the Final Sample 
SNP 
Abstraction 
& Mental 
Flexibility Attention 
Verbal 
Memory 
Facial 
Memory 
Spatial 
Memory 
Spatial 
Processing 
Sensorimotor 
Dexterity 
Emotional 
Processing 
SNP8NRG221132     0.0152           
SNP8NRG221533 0.0178               
rs10096573                 
rs4298458                 
SNP8NRG241930                 
rs1081062       0.0217*^ 0.0022*       
rs13274954       0.0088*^ 0.0018*       
rs4566990                 
rs1354335         0.0514       
rs1354336   0.0354*^             
rs13256173                 
rs1354334                 
SNP8NRG444511                 
rs776401                 
rs1473438                 
rs1462893                 
rs10954821                 
rs726908                 
rs10954855   0.0396 0.0258 0.0152   0.0018*^     
rs2439306                 
rs2466062                 
rs3924999   0.0303             
rs2466060   0.0072       0.0372     
rs2439272           0.0234     
rs6468121                 
rs2466044       0.0537         
rs2466058       0.0343         
rs2466049       0.0349         
rs723811                 
rs6988339                 
rs2975498                 
rs2919382                 
rs2976525           0.0501   0.049 
rs4262285                 
rs3735776     0.0347 0.0212         
rs4512342                 
rs10503929 0.0354           0.0439   
rs6992642                 
rs3735781                 
rs3735782                 
Associations significant after Bonferroni correction (p≤0.0051) are bolded.  
Shaded cells correspond to significant associations in the final sample when education was not a covariate (Table 17) 
*QTDT results reported due to significant trait stratification. 
^Associations with significant stratification and opposite signs for between- and within-family beta weights 
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When compared to the associations found in the total final sample, seven associations 
remained significant, while eighteen new associations were found in this sample and eleven 
previous associations were lost. When these results were adjusted by Bonferroni correction, as 
described previously, three associations remain significant: spatial memory and rs1081062 
(p=0.0022; QTDT), spatial memory and rs13274954 (0.0018; QTDT), and spatial processing and 
rs10954855 (p=0.0018; QTDT). None of these associations were significant in the final sample 
or the unaffected sample.  
 
3.4  ASSOCIATION BETWEEN NRG1 VARIATION AND SCHIZOPHRENIA 
Finally, associations between NRG1 SNPs and affected status (e.g., diagnosis of schizophrenia 
or schizoaffective disorder-depressed) were calculated to determine whether NRG1 was 
associated with schizophrenia in the final sample. One significant association was found: 
rs1081062 (p=0.0514; QTDT). The lack of findings here is likely influenced by the small 
number of affected participants in the final sample.  
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4.0   DISCUSSION 
4.1  SUMMARY OF FINDINGS 
As expected, we found that cognition is heritable in this schizophrenia family sample, helping to 
confirm the generalizability of our results. In addition, this study found evidence that variation in 
NRG1 is significantly associated with cognitive performance in the total affected and unaffected 
sample, as well as in the unaffected and “No Diagnosis” subsamples; albeit with some 
differences in the associations found in each sample. This evidence suggests NRG1’s putative 
mechanism of increasing risk for schizophrenia may be due, in part, to its relationship to 
cognition.   
Associations were re-analyzed in progressively “cleaner” samples to better understand 
the associations between NRG1 and cognition in the context of schizophrenia, and to control for 
potential effects of psychopathology. Although the specific associations varied by sample, each 
sample had significant associations, even after correction for multiple comparisons was made. 
Over all of the samples, the domain of attention consistently had the most, or nearly the most, 
significant findings when compared to other cognitive areas. This may suggest that NRG1 plays 
an especially important role in attention.  
There was also one significant association between NRG1 SNPs and the diagnosis of 
schizophrenia or schizoaffective disorder-depressed in the current study, although it was non-
significant after correcting for multiple comparisons using a Bonferroni (pB = 0.0290) correction. 
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This may suggest that the current NRG1 SNP set is not associated with schizophrenia; 
however, it may also be due to the small sample of affected participants leading to low power to 
detect associations between the disorder and individual SNPs. Given the large literature showing 
a positive association between NRG1 and schizophrenia, the latter seems more likely. 
To better understand the significant associations in the current study, we will discuss the 
following SNPs in greater detail: rs1081062, rs13274954, rs1354336, rs10954855, rs2466060, 
and rs10503929. The LD within this group of SNPs was less than or equal to 0.2, except for the 
following: rs1354336 and rs1081062 (LD = 0.4), rs1354336 and rs13274954 (LD = 0.4), and 
rs1081062 and rs13274954 (LD = 1.0). As seen in Table 25, these SNPs were significant after 
Bonferroni correction (pB = 0.0051) in any given cognitive domain and subsample, and/or were 
significant at the p≤0.05 level for all of the subsamples in a specific domain. They are discussed 
in order of basepair (5’ to 3’).  
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Table 25. SNPs Significant after Bonferroni Correction (p≤0.0051) and/or Significant (p≤0.05) 
in All Subsamples 
Marker Domain(s) Sample(s) p-value 
Beta 
within^ 
Beta 
between^ 
Effect of 
the Minor 
Allele 
rs1081062 Spatial Memory “No Diagnosis”  0.0022* 0.5769 0.0598 Benefit 
rs13274954 Spatial Memory “No Diagnosis” 0.0018* 0.6066 0.0835 Benefit 
rs1354336 Attention 
Final (without education) 0.0021* -0.5691 0.2479 
Detriment 
Final (with education as 
a covariate) 
0.0030* -0.5624 0.2929 
Unaffected 0.0044* -0.5171 0.2714 
“No Diagnosis” 0.0354* -0.5001 0.2957 
rs10954855 
Spatial 
Processing “No Diagnosis”  0.0018* 0.7375 -0.0759 
Verbal Memory 
Final (without education) 0.0127 0.3125 0.05 
Benefit 
Final (with education as 
a covariate) 
0.0338  0.2923 0.0179  
Unaffected 0.0433 0.1953 0.0524 
“No Diagnosis” 0.0258 0.264 0.1688 
rs2466060 Attention 
Final (without education) 0.0044* 0.4221 -0.0275 
Benefit 
Final (with education as 
a covariate) 
0.0077  0.4334 0.0235  
Unaffected 0.0077 0.3218 -0.0787 
“No Diagnosis” 0.0072 0.5098 -0.0945 
rs10503929 Abstraction & Mental Flexibility 
Final (without education) 0.0318 -0.3942 0.0364 
Detriment 
Final (with education as 
a covariate) 
0.0090  -0.4041 -0.0046  
Unaffected 0.0534 -0.3363 -0.0596 
“No Diagnosis” 0.0354 -0.5115 -0.0851 
Associations significant after Bonferroni correction are bolded. 
*QTDT results reported due to significant trait stratification 
    ^A positive value indicates that the minor allele confers a benefit, while a negative beta weight value indicates that 
the minor allele confers a detriment to cognitive performance. 
 
 
4.1.1  SNP-wise Findings & Comparison to Current Literature 
4.1.1.1 Marker rs1081062. SNP rs1081062 was found to be significant in the domain of 
spatial memory in the “No Diagnosis” sample, even after correction for multiple comparisons. 
Although there was significant stratification in this analysis, both the between- and within-family 
64 
 
betas had positive signs. In this association, the minor allele (C) was associated with better 
performance in spatial memory than the major allele (T). This SNP was originally associated 
with schizophrenia by Fukui et al. (2006) in a Japanese population, where homozygotes of the 
minor allele (genotype CC) had a significantly increased risk of schizophrenia compared to the 
heterozygote and major allele homozygotes (TT). However, two other recently published studies 
failed to find an association between this marker and schizophrenia, including a replication 
attempt in a Japanese sample (Shiota et al., 2008) and a study utilizing a Bulgarian sample 
(Georgieva et al., 2008). To our knowledge, no studies of rs1081062 and cognition exist in 
patient or control samples. 
4.1.1.2 Marker rs13274954. As expected based on its LD with rs1080162 (LD=1, see 
above), marker rs13274954 was found to be significant in spatial memory in the “No Diagnosis” 
sample, even after Bonferroni correction. Stratification was significant in this association, but 
both between- and within-family beta weights were positive. The minor allele (A) was associated 
with better spatial memory than the major allele (T). To our knowledge, no studies of 
rs13274954 and cognition exist in patient or control samples. 
4.1.1.3 Marker rs1354336. SNP rs1354336 was significantly associated with attention in 
all samples of the current study. Significant stratification was detected in this association for all 
samples; in each, the within-family beta was negative, while the between-family beta was 
positive. Specifically, the major allele (T) was associated with better efficiency in attention in all 
samples compared to the minor allele (C). This SNP is near several of the microsatellites 
(specifically marker 420M9-1395) within the original haplotype blocks associated with 
schizophrenia in a European sample by Stefansson, et al. (2002, 2003) and others. To our 
knowledge, no studies of rs1354336 and cognition exist in patient or control samples. 
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4.1.1.4 Marker rs10954855. In the current study, rs10954855 was found to be 
significantly associated with spatial processing in the “No Diagnosis” sample, even after 
Bonferroni correction. Significant stratification was detected in this association; the within-
family beta was positive, while the between-family beta was negative. In addition, it was also 
significantly associated with verbal memory in all samples of the study, albeit not always 
surviving Bonferroni correction. No significant stratification was detected in these associations. 
In both spatial processing and verbal memory, the minor allele (A) was associated with 
better performance compared to the major allele (T). This SNP lies near microsatellite 317J8-
2123, which was associated with schizophrenia in a Chinese sample by Li et al. (2004). To our 
knowledge, no studies of rs10954855 and cognition exist in patient or control samples. 
4.1.1.5 Marker rs2466060. Marker rs2466060 was significantly associated with attention 
in all samples of the current study, but did not always survive Bonferroni correction. Significant 
stratification was detected in this association in the final sample; the within-family beta was 
positive, while the between-family beta was negative. The minor allele (A) was associated with 
better attention in each sample. It is located near microsatellite 317J8-4858 which was associated 
with schizophrenia in a Chinese sample by Li et al. (2004). Unlike the other highly significant 
markers whose genotyping failure rate ranged from 0.00-1.19%, this SNP had a failure rate of 
10.74%. Thus despite its consistent significance in all samples at the p≤0.05 level, its high failure 
rate requires us to take caution in our interpretation of this marker. To our knowledge, no studies 
of rs2466060 and cognition exist, in patient or control samples. 
4.1.1.6 Marker rs10503929. Marker rs10503929 was significantly associated with 
abstraction and mental flexibility in all samples of this study. No significant stratification was 
detected in any of the samples studied. The major allele (T) was associated with better 
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abstraction and mental flexibility than the minor allele (C). Importantly, this is a missense non-
synonymous SNP that leads to the substitution of a methionine (M) to threonine (T) amino acid 
if a T to C allele change occurs. Although no published reports have suggested what the effect of 
this substitution might be, M is a much larger molecule than T (149.21 g mol-1 compared to 
119.12 g mol-1) (Nelson & Cox, 2000) and has a different secondary structure (helical-favoring 
compared to C-beta-branched extended-favoring), although both are polar and neutral amino 
acids (Nelson & Cox, 2000). This SNP has been associated with schizophrenia in several studies, 
including Schwab, et al. (2006; Australian sample), Baines, et al. (2008; Costa Rican sample), 
and Rosa, et al. (2007; Spanish sample). In the Rosa study, there was a significant over-
transmission of the C allele compared to the T allele in the families with patients with psychosis. 
To our knowledge, one study of rs10503929 and cognition has been published (Hong, Wonodi, 
Stine, Mitchell, & Thaker, 2008) that found no association between this marker and pre-pulse 
inhibition in individuals with schizophrenia or healthy controls. 
4.1.1.7 Other NRG1 Markers Associated to Cognition in Previous Literature. Despite 
significant associations between SNP8NRG243177/rs6994992 and cognition in previous studies, 
this marker failed the SNPlex algorithm in multiple design submissions and could not be 
analyzed in the current study. SNP8NRG221533/rs13268724 was found to be associated to 
sustained attention in one previous study (Stefanis et al., 2007). In the current study, it was 
associated with accuracy in abstraction and mental flexibility in the total final sample (p=0.0497) 
and efficiency in abstraction and mental flexibility in the “no diagnosis” sample (p=0.0178), but 
not with attention in any sample. Finally, microsatellites were not tested in the current study, so 
433E1006’s association with sustained attention and verbal working memory could not be 
assessed. 
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4.1.2 Stratification Findings 
Many of the significant associations between NRG1 and cognition had significant stratification, 
including stratification where the sign of the beta weight differed between- and within-families, 
indicating that one allele conferred cognitive advantage within families, while the alternative 
allele conferred benefit between families. Although this was unexpected, the between-family 
measure is sensitive to population stratification or admixture, while the within-family measure is 
safe from such problems due to the family structure of the study. Such stratification is due to the 
combination of families across different population strata and only affects the between-family 
beta (Abecasis, Cardon, & Cookson, 2000; Havill et al., 2005). Abecasis et al. (2000) found that 
spurious associations between the marker and phenotype are contained within the between-
family component, while the within-family beta estimates only the additive genetic value, even 
when significant stratification is present. However, stratification is generally expected to lead to 
greater associations between- than within-families, and thus it is unusual to have the between-
family component to be less than the within-family component. In the current study, there are 
frequently associations in which the signs of the between- and within-family betas are opposite, 
which may indicate that some between-family factor is associated with the allele, leading to 
significant stratification in which the direction of the association is different between compared 
to within families.  
In addition, stochastic, or random, variation cannot be ruled out as the cause of 
stratification in this study. However, some of the most significant associations, as defined by p-
values, were highly stratified with opposite beta weight signs (see Table 25), making random 
error less likely of an explanation. In addition, the threshold for stratification was set to α = 0.05 
and was not corrected for multiple comparisons in order to be conservative in the use of QTLD, 
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given its lack of robustness to stratification. However, the high number of overall comparisons 
without correction make it likely that a Type I error occurred and that at least some associations 
with significant stratification are due to chance (Havill et al., 2005).  
 
4.2  CONCLUSIONS 
Although the specific associations that were significant differed somewhat among subsamples, 
each sample had between 14-25 significant (p≤0.05) associations, encompassing multiple SNPs 
and multiple cognitive domains. The numerous significant findings in progressively “cleaner” 
sub-samples may suggest that variation in NRG1 is more directly associated with cognition and 
is not solely secondary to an effect of schizophrenia or psychopathology. These associations may 
suggest a role for NRG1 in cognition that is a mediating risk factor for schizophrenia and/or 
psychopathology more generally. It is also possible that these associations with cognition are 
irrelevant to schizophrenia, but the literature on NRG1 and schizophrenia argues against this 
possibility.  
 In considering the cognitive domains separately from individual SNPs, attention 
consistently had the most, or nearly so, significant associations over all of the samples assessed. 
Spatial memory generally had the fewest significant findings. This may suggest that over all of 
the domains tested, NRG1 may have a more specific role in the maintenance of attention, while 
playing only a small role in spatial memory.  
 Considering only the SNPs with the most significant results (rs1081062, rs13274954, 
rs1354336, rs10954855, rs2466060, and rs10503929), four are in the 5’ UTR, one is between 
exons 5-6, and one is in exon 9. LD among these SNPs is less than or equal to 0.40, except for 
rs1081062 and rs13274954, which are in perfect LD and share the same associations. In addition, 
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the low genotyping failure rates (0.00-1.19%; except for rs2466060 (10.74%)) among these 
SNPs allow us to be relatively confident with these findings, despite significant stratification.   
 Of these SNPs, the most promising associations encompass four SNPs and three 
cognitive domains. Specifically: rs1354336 and attention, rs10954855 and verbal memory, 
rs2466060 and attention, and rs10503929 and abstraction and mental flexibility. Three of these 
SNPs (rs1354336, rs10954855, and rs2466060) were chosen for the current study due to their 
close proximity to microsatellites identified as being associated with schizophrenia by previous 
studies, while the fourth (rs10503929) was suggested by three association studies.  
 Perhaps the most interesting association in the current study was between rs1354336 and 
attention. This association was significant in every sample studied, and survived Bonferroni 
correction in all but the “No Diagnosis” sample. In addition, this marker lies in close proximity 
to a microsatellite within the original haplotype blocks associated to schizophrenia by Stefansson 
et al. (2002, 2003), making it potentially useful for better understanding the association between 
NRG1 and cognition within the context of schizophrenia. However, rs1354336 had significant 
stratification with opposite signed beta weights in its associations with attention in every sample.  
 A more conservative approach may be to follow-up on the association of rs10503929 and 
abstraction and mental flexibility. This association was significant for every sample, but did not 
always survive Bonferroni correction. It has been associated to schizophrenia by three studies, is 
a missense non-synonymous variant and has intriguing functional implications, and had no 
significant stratification within any sample in the current study.  
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4.3  LIMITATIONS 
Although this study provides evidence for a potentially important role of NRG1 in cognition 
within multiplex families with schizophrenia, it has several limitations. First, the number of 
participants with schizophrenia or schizoaffective disorder-depressed in the sample was small. 
This prevented us from testing for associations with NRG1 and cognition in the patient-only 
sample. In addition, the general lack of associations between NRG1 and affected status was also 
likely affected by this low power.  
 A second important limitation of this study was a lack of a genotyped control group. 
Although we used progressively “cleaner” diagnostic sub-groups of the main sample to estimate 
the effect of NRG1 and cognition within the context of schizophrenia and general 
psychopathology, it is difficult to determine whether the role of NRG1 in cognition is relevant to 
schizophrenia or is a more general effect.  
 
4.4 FUTURE DIRECTIONS 
Future directions aimed at resolving the limitations in the current study include further narrowing 
the SNP set and assessing the relationship of NRG1 and cognition and its specificity to 
schizophrenia. First, a Bayesian analysis (Blangero et al., 2005) would allow the combination of 
SNPs that best predicts cognitive performance to be determined. Next, a genetic cross correlation 
analysis would allow a better understanding of the role of NRG1 in cognition and schizophrenia. 
One specific question that might be assessed here is whether the genes contributing to cognitive 
performance are correlated with those that contribute to schizophrenia within families. Finally, 
the addition of a control group would allow us to assess the previous associations to determine 
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whether NRG1 is related to cognition in a healthy sample, thus further parsing the role of NRG1 
and cognition in schizophrenia.  
 Other directions in answering the NRG1-cognition question include studying more 
markers within NRG1, specifically the microsatellites found to be associated with schizophrenia 
in the HapICE and HapIRE haplotypes and by Li et al. (2004), especially as SNPs in close 
proximity to three of those microsatellites were found to be significantly associated with 
cognition in this study. In addition, determining what implications the M to T amino acid change 
might have for SNP rs10503929 may provide clues to its role, if any, in attention. 
Finally, the use of methods and models that incorporate epistatic and environmental 
influences that might play a moderating role in the relationship between NRG1 and cognition are 
necessary to better understand these associations. There is evidence that variation in both NRG1 
and ErbB4, as well as the interaction between those variants, is associated with an elevated risk 
for schizophrenia (Norton et al., 2006). A subsequent study (Benzel et al., 2007) confirmed the 
interaction between ErbB4 and NRG1, in addition to finding evidence of epistasis between 
NRG1-NRG2 and NRG1-NRG3 in a sample of patients with schizophrenia and control 
participants. Another recent study found a ten-fold increase in risk for schizophrenia depending 
on the combination of variants in both NRG1 and Interleukin-1β (Hanninen et al., 2008). Such 
findings suggest that intergenic interactions between NRG1 and other genes may increase 
susceptibility to schizophrenia and may also help mediate the role of NRG1 in cognition. 
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